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ABSTRACT

One of the characteristics of advanced tumors is the evasion of the immune
system. There are multiple methods that tumor cells employ to achieve this including
reducing the expression of activating ligands on the cell surface and a shift in the tumor
microenvironment toward pro-tumor cytokines. The purpose of this research is to
develop a novel bifunctional fusion protein that will target these two deficiencies in the
tumor microenvironment and activate killer cells that are already present. The proposed
protein combines the extracellular domain of a ligand for the killer cell activating
receptor NKG2D and Interleukin-12 (IL-12). It is hypothesized that when expressed by
tumor cells by gene therapy, the protein will simultaneously activate NK and other killer
cells using the NKG2D receptor, and deliver a locally high dose of IL-12 to the tumor
microenvironment where it can interact with the IL-12 receptor and enhance cytotoxicity.
We first engineered a mouse version of the protein including the extracellular
domain of the NKG2D ligand mouse UL-16-binding protein-like transcript 1 (MULT1E)
and mouse IL-12 (mIL-12). The fusion protein (MULT1E/mIL-12), when expressed by
engineered tumor cells, indeed activated NK cells in vitro as assayed by increased
production of interferon-γ (IFN-γ) and cytotoxicity and significantly reduced tumor
growth in vivo.
To expand the concept of developing a novel bifunctional fusion protein for
enhanced NK cell activation to human killer cells, the mouse NKG2D ligand MULT1
was replaced with the extracellular domain of a human NKG2D ligand MHC class I
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polypeptide-related sequence A (MICA). The fusion protein, when expressed by
engineered tumor cells, indeed activated NK92 cells as measured by an increase in IFN-γ
production and an increase in cytotoxicity of tumor cells. The fusion protein was also
able to increase the proliferation of human peripheral blood mononuclear cells (PBMCs)
and augment their production of IFN-γ.
Although our results are preliminary, they confirm the hypothesis that a fusion
protein of the extracellular domain of an NKG2D ligand and IL-12 is effective in
activating killer cells in vitro and in animal models. The idea represents a novel
immuno/gene therapy for treating human cancers.
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CHAPTER ONE

LITERATURE REVIEW

Cancer
It is projected that by 2030 there will be approximately 26 million new cancer
cases and 17 million cancer deaths per year.1 Although cancer is a heterogeneous disease
with diversity not only between cancer types but also between cells within the same
tumor, Hanahan and Weinberg have proposed eight hallmarks of cancer. These
hallmarks describe the capabilities that normal cells acquire during tumorogenesis and
include sustaining proliferative signaling, evading growth suppressors, activating
invasion and metastasis, enabling replicative immortality, inducing angiogenesis,
resisting cell death, deregulating cellular energetics, and avoiding immune destruction.2
Cancer Immunoediting
In 1909, Peter Ehrlich was the first to propose that the immune system suppressed
the growth of what could be an overwhelming amount of carcinomas.3 Because there
was a lack in understanding of how this process occurred, the popularity of this theory
waned. Years later, when the cellular mechanisms of immunity (including tumor specific
antigens) were beginning to be elucidated, interest returned to the interactions between
cancer and the immune system.4 Burnet and Thomas authored the cancer
immunosurveillance hypothesis in 1957 that stated lymphocytes recognize and eliminate
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continually arising, nascent transformed cells.4 As knowledge of the immune system has
increased, it has become clear that cancer immunosurveillance is just one step of the
larger immunoediting process that includes both adaptive and innate immunity.3
Cancer immunoediting (Figure 1.1) is a dynamic process consisting of three
phases: elimination, equilibrium, and escape.5 The elimination step includes the original
idea of immunosurveillance. As the newly formed tumor begins to grow, an
inflammatory response is elicited and innate immune cells (NKT, NK, and γδ T cells) are
recruited to the area.3 These immune cells are activated by a change in the structures
found on the surface of transformed cells, including NKG2D ligands, and produce
cytokines that aid in cell death and the recruitment of CD4+ and CD8+ T cells.5 At the
end of the elimination phase, any cells displaying aberrant surface structures have been
removed. The equilibrium phase, which can occur over a period of several years, is
sometimes referred to as dormancy. A dynamic equilibrium is reached between the
rapidly mutating tumor and the host immune system following a pattern of Darwinian
selection.4 At the end of the equilibrium phase, the tumor cells that remain have been
selected for their ability to evade immunosurveillance. This begins the escape phase
where the selected tumors can grow in an immunologically intact environment and
become clinically detectable.3
Tumor Microenvironment
Although cancer immunoediting can partially account for the immunoevasion
seen in many cancers, it is also important to examine the immunosuppressive
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Figure 1.1 Two pathways NK cells use to cause target cell death. Exocytosis of granules containing perforin and
granzymes triggers apoptotic cell death. Apoptosis can also be caused by binding of the Fas ligand to the Fas
receptor of the target cell.20
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characteristics of the tumor microenvironment. It has been demonstrated that advanced
cancer patients have spontaneously generated tumor-antigen-specific immune responses
such as CD8+ T cells against specific epitopes and the presence of tumor-specific
antibodies. This indicates that immunologic ignorance is not to blame in all cases.6
There are several regulatory cell populations that are commonly found within the
tumor microenvironment that function to reduce the effectiveness of activated immune
cells including regulatory T cells , myeloid derived suppressor cells, and tumor associated
macrophages.6 Regulatory T cells, or Tregs, can suppress the effector function of CD4+
and CD8+ T cells, natural killer cells, natural killer T cells, B cells, macrophages, and
dendritic cells. They do this by the secretion of immunosuppressive cytokines,
modification or killing of antigen presenting cells (APCs), and cell-contact-dependent
suppression.7 Along with promoting tumor angiogenesis and metastasis, myeloid derived
suppressor cells (MDSCs) can inhibit both adaptive and innate immunity. T cells are
suppressed by the depletion of L-arginine, from the microenvironment by MDSCs that
express high amounts of the enzymes arginase 1 and iNOS.8 MDSCs can also inhibit
TCR binding in T cells by both nitrating the tyrosines (through the release of ROS and
peroxynitrite) and downregulating the production of the TCR ζ-chain.9,10 Tumor
associated macrophages, or TAMs are predominately polarized type II due to the
increased levels of IL-10, IL-4, and IL-13 in the tumor microenvironment and promote
tumor growth in several different ways. First, TAMs can promote tumor growth and
survival through the production of growth factors and aid in metastasis by digesting
extracellular matrix. TAMs can directly suppress T cell activation and proliferation
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through the production of prostaglandins, IL-10, and indoleamine dioxigenase (IDO)
metabolites and indirectly through the induction of Tregs.11
Tumor cells are also capable of releasing their own immunosuppressive
chemicals. Some of these immunosuppressive chemicals are ligands that are normally
expressed on the surface of the cell that get shed, releasing a soluble form. For example,
Baltz, et al. showed that a soluble form of glucocorticoid-induced TNFR-related protein
ligand (sGITRL) is released by tumor cells into the microenvironment and reduces NK
cell cytotoxicity and IFN-γ production in a concentration dependent manner.12 Other
chemicals are normally produced by noncancerous cells but tumorigenesis causes these
cells to produce an aberrant amount. Transforming growth factor-β (TGF-β) production is
increased in many types of tumors. TGF-β reduces the effectiveness of CD4+ and CD8+
T cells, natural killer cells, dendritic cells, and type I neutrophil and macrophage
development. It also induces the generation of Tregs, type II neutrophils and
macrophages, and increases the immune suppression function of MDSCs.13
Natural Killer Cells
Human natural killer cells (NK cells) are a very important part of the innate
immune system and make up approximately 15% of all circulating lymphocytes.14,15 NK
cells are granulocytes that can rapidly kill pathogen-infected cells and tumor cells but are
tightly regulated by a balance of inhibitory and activating receptors.
Most inhibitory receptors are specific to MHC class I molecules that are found on
every nucleated cell of the body. MHC class I molecules present cytosolic peptides on
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the surface of a cell. If the peptides presented are “self,” the cytolytic activity of NK
cells will be inhibited. The inhibitory receptors, including killer cell immunoglobulinlike receptors (KIRs) and leukocyte immunoglobulin-like receptors (LILRs), contain an
immunoreceptor tyrosine-based inhibitory motif (ITIM) that, when phosphorylated,
recruits phosphatases to the interface between the NK cell and its prospective target
cell.16 The tyrosine phosphatases then dephosphorylate the protein substrates of the
tyrosine kinases linked to activating receptors, suppressing their activity.17 This activity,
however, is spatially regulated and only affects the activating receptors nearby, allowing
the NK cell to be subsequently activated by target cells lacking ligands for the inhibitory
receptors or containing many ligands for activating receptors.17
NK cells, unlike T and B cells, have many different activating receptors including CD16,
NKp46, NKG2D, CD244, CD226, and CD2. It appears that only CD16 can be induced
to cause cytotoxicity independently. All other activating receptors require synergism
with other receptors to produce a cytotoxic response.18 The variety of activating
receptors induces several common signaling pathways, including ITAM/DAP12, DAP10,
and ITSM, all leading to a calcium flux.17 When an NK cell is activated, cytotoxic
granules are exocytosed into the extracellular space between the NK cell and the target
cell in a calcium dependent manner.19 NK cell granules contain proteins including
perforin, granzymes, and granulysin. Perforin creates transmembrane pores in the target
cell and it may also be important in disrupting endosomal trafficking after it enters the
cytoplasm. Granzymes work with perforin to coordinate apoptotic death of the target
cell. These proteases can cleave lamins to disrupt the nuclear envelope, create single-
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stranded DNA nicks, and activate caspase-mediated apoptosis. Granulysin exhibits lytic
activity against both microbes and tumors.20 Activated NK cells also have an
overexpression of the Fas ligand.21 When the Fas ligand comes in contact with the Fas
expressing target cell, a death-inducing signaling complex (DISC) is formed.
FADD/MORT, an adaptor, binds to Fas and engages procaspase-8. Autoproteolysis of
procaspase-8 to caspase 8 occurs due to the “induced proximity” model. Caspase 8 will
activate caspase-3 and caspase-7 which induce cellular apoptosis (Figure 1.2).22
In vitro Manipulated Natural Killer Cell Therapy
With the important role that NK cells play in recognizing and destroying tumor
cells in vivo, they have been considered a hopeful target for cancer immunotherapy. It
was first shown in the early 1980s that lymphokine-activated NK cells are able to actively
clear circulating tumor cells during the first four hours after inoculation.23 Later that
decade, it was shown that NK cells can kill MHC class I deficient tumor cells that have
evaded T cell cytotoxicity.24,25 The use of autologous lymphokine-activated killer cells
looked promising, but soon met difficulties because it required the co-administration of
IL-2, which is very toxic at high systemic doses26–28. Phase II and III clinical trials also
showed that there was only a 15-20% response rate which is not superior to IL-2
monotherapy or IL-2 combined with IFN-α.29 This may be because of the presence of
ligands on tumor cells for inhibitory KIRs on NK cells, resulting in the inactivation of the
killer cells or an increase in the Treg cell population after IL-2 administration.30
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Figure 1.2 Two pathways NK cells use to cause target cell death. Exocytosis of granules containing perforin and
granzymes triggers apoptotic cell death. Apoptosis can also be caused by binding of the Fas ligand to the Fas
receptor of the target cell.20
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In an effort to remedy this, NK cell donors were chosen with KIR-ligand
mismatch.29 Acute myeloid leukemia patients undergoing haploidentical stem cell
transfer with KIR-ligand mismatch showed improved disease-free survival and reduced
graft-versus-host disease (GVHD).31 The clonal NK cell line, NK-92, has also been the
subject of study because it lacks KIRs. The highly cytolytic NK-92 cells are activated by
IL-2 and have a broad spectrum of tumor targets, however, the IL-2 activation can only
be maintained in vivo for 48 hours.32 In order to provide a constant supply of IL-2 for the
NK cells in vivo and without using high doses of systemic cytokine, IL-2 secreting NK92 clones were engineered that continually release a small amount of IL-2 allowing for
prolonged activation (NK-92 MI).33 NK-92 therapy has been shown to be effective for
leukemia and trastuzumab resistant breast tumor cells in vitro, and malignant melanoma
and renal cell carcinoma in vivo.33–36 These treatments have also been more effective
than lymphokine-activated killer cells.33
NKG2D: A Natural Killer Cell Activating Receptor
Another approach is activating NK cells in vivo through activating receptors. The
activating receptor NKG2D is found as a homodimer on NK cells, γδT cells, some CD8+
αβT cells, NKT cells, and a subset of CD4+ αβ T cells and plays an important role in
cancer immunity (Table 1.1).37–39
NKG2D ligands include MHC class I related chain (MIC) A and B and the UL-16
binding protein family in humans and RAE-1, H-60, and mouse UL-16 binding proteinlike transcript (MULT1) in mice.40 The transmembrane domain of NKG2D associates
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Table 1.1 Expression of NKG2D by immune cells. There is a differential expression of the activating
receptor NKG2D on mouse and human cells.39
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with the transmembrane domain of the DAP10 homodimer in humans forming a
hexadimer receptor complex with one NKG2D homodimer and two DAP10 homodimers.
In mice, two forms of NKG2D exist: NKG2D-L and NKG2D-S depending on the number
of amino acids in the cytoplasmic domain. NKG2D-L can only pair with DAP10.
However, NKG2D-S can pair with either DAP10 or DAP12.17
When DAP10 is phosphorylated, signaling can occur through the p85 subunit of
phosphatidylinositol-3-OH kinase (PI3K) or the adaptor Grb2 binding to the YINM
signaling motif. Both p85 and Grb2 binding lead to a Ca2+ influx, NKG2D mediated
cytotoxicity, actin cytoskeleton reorganization, and microtubule polarization. Binding of
p85 to DAP10 also induces production of phosphatidylinositol-3,4,5-triphosphate (PIP3)
in the immune synapse between the activated NK cell and the target cell.17
DAP12 contains an immunoreceptor tyrosine-based activation motif (ITAM) in
the cytoplasmic domain which, when phosphorylated, binds the tyrosine kinases Syk or
ZAP-70 (Figure 1.3). Downstream results of phosphorylation include actin cytoskeleton
reorganization, release of cytolytic granules, and the transcription of cytokine and
chemokine genes. Because of species specific expression of DAP10 and DAP12, mouse
NKG2D ligand produce both cytotoxicity and cytokine release whereas human NKG2D
ligands preferentially produces cytotoxicity.17
Mouse UL-16 Binding Protein-Like Transcript 1 (MULT1)
MULT1 is an NKG2D ligand with a protein sequence similar to human UL16binding protein 3 (ULBP3).41 The 37.1 KD protein contains two MHC class I-like α
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Figure 1.3 NKG2D Receptor. The mouse has both NKG2D-S and NKG2D-L receptors. The NKG2D-S can
pair with either DAP12 or DAP10. NKG2D-L can pair with DAP10. The one form of human NKG2D only
pairs with DAP10.111
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domains.42 Unlike ULBP or the RAE1 family proteins that are anchored to the cell
membrane by glycosylphosphatidylinositol (GPI), MULT1 is a type I transmembrane
protein with both a transmembrane and a cytoplasmic domain.42 MULT1 transcripts are
detectable in many normal tissues including thymus, spleen, lymph nodes, liver, heart,
and lung, unlike other mouse ligands for NKG2D.42 However, no surface expression is
detected when stained with NKG2D tetramers suggesting that MULT1 is regulated posttranscriptionally. Nice et al. showed that MULT1 is regulated posttranslationally through
ubiquitination dependent on lysines in its cytoplasmic tail and lysosmal degradation
under normal conditions.43 Degradation and uniquitination of MULT1 can be decreased
by heat shock or ultraviolet irradiation leading to higher surface expression. The same
results were not seen with ionizing radiation, 5-FU, cisplatin, or mitomycin C.43
MHC Class I Chain-Related Protein A (MICA)
MHC class I Chain-Related Protein A (MICA) is a human NKG2D ligand.
Unlike MULT1, under normal conditions, the mRNA for this nonconventional HLA class
I molecule is expressed only in intestinal and thymic epithelium.44,45 However, under
stress (like tumorigenesis and exposure to intracellular pathogens), many epithelial cells
can upregulate MICA expression.46 The highly polymorphic MICA gene codes for a
membrane-bound protein made of 383 amino acids and a relative molecular mass of
43kDa.47 Although MICA conserves the α1-3 extracellular domains seen in classical
MHC class I molecules, the MHC peptide-binding groove is not open to allow peptide
presentation.39

	
  

13	
  

There has been a correlation found between the presence of soluble MICA in the
sera of cancer patients and cancer stage and metastasis.48 This correlation is commonly
attributed to downregulation of NKG2D receptor expression on effector cells.49
However, recent studies have shown that the NKG2D receptor downregulation may be
mediated instead by other factors including TGF-β and membrane bound MICA. It has
also been shown that the downregulation of NKG2D receptor caused by soluble MICA is
at supraphysiological levels.50
Cancer Immunoediting Affects NKG2D Ligands
NKG2D ligands play an important role in the first stage of immunoediting.
During the early stages of cancer development, DNA damage can cause the upregulation
of NKG2D ligands, allowing the cells to be easily recognized and removed by NK cells
(Table 1.2).40 B6 and BALB/c mice treated with anti-NKG2D mAb showed an increase
in sarcoma incidence after exposure to methylcholanthrene (MCA) indicating that
functional NKG2D reduced sarcoma incidence.51 As the cancer progresses, however,
tumor cells have found ways to downregulate surface NKG2D ligands. It has been
shown that the extracellular domains of MICA can be shed by tumor cells using
proteolytic cleavages, thus preventing activation of cytotoxic immune cells.52 The
immune system may also aid in selecting against tumor cells that maintain NKG2D
ligand expression.

	
  

14	
  

Table 1.2 Induction of NKG2D ligands by stress pathways. NKG2D ligand expression is upregulated in
response to stress within the cell. Different stress pathways cause upregulation of different ligands.112
Refs refer to references in original paper.
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NKG2D Ligand Immunotherapy
It should be possible, then, to reinitiate an immune response by upregulating
NKG2D ligands in cancer cells. In 2001, groups at both the University of California,
Berkeley and the University of California, San Francisco concurrently, but separately,
showed that by transfecting several tumor cell lines to express Rae1 or H60 using a
retroviral vector, tumor growth could be reduced or abrogated completely.53,54 The
Berkeley group showed that along with activating NK cells, CD8+ T cells were also
stimulated by some of the tumor cell lines leading to a specific immune memory response
even against the parental non-transfected tumor cells.53 However, the group from San
Francisco was not able to show the same response with Rae1 transfected RMA
lymphoma tumors.54 Ectopic expression of ULBP1, ULBP2, or ULBP3 has also been
shown to cause reduced tumor growth.55 Others have shown that upregulating MICA on
glioma and melanoma cells promotes NK-mediated cytolysis and induces T cell
response.56,57
NKG2D ligands have also been used in modified forms. For example, a fusion
protein of MULT1 and Fas has been shown to significantly decrease tumor cell growth in
mouse models. The extracellular domain of the MULT1 NKG2D ligand functions as an
activator of NK cells in the environment whereas the transmembrane and intracellular
domains of Fas lead to Fas-mediated apoptosis. The addition of Fas increased the tumor
suppressing abilities of the MULT1.58 Additionally, the therapeutic value of this fusion
protein was affirmed by the production of a replication-deficient adenovirus vector that,
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when injected into a subcutaneous tumor, caused a significant decrease in tumor
growth.59
Another approach is to generate a bispecific secreted protein where the NKG2D
ligand domain is conjugated to an antibody to direct the protein to the tumor cell surface.
The bispecific protein ULBP2-BB4 binds both to CD138, which is overexpressed on the
surface of a variety of malignant cells, through the BB4 moiety and to NK cells using the
ULBP2 moiety.60 The combination therapy of ULBP2-BB4 protein and peripheral blood
lymphocytes (PBLs) was highly effective in eradicating tumors in a multiple myeloma
xenograft model.60 By using a purified protein, there is no need for the sometimes
controversial gene delivery.
Interleukin 12
Interleukin 12 (IL-12), also known as NK cell stimulatory factor 2, is also an
activator and initiator of NK cell proliferation. It is a heterodimeric cytokine consisting
of the disulfide-linked subunits p35 and p40 (named according to their molecular
weight).61 The IL-12 receptor is composed of two subunits: IL-12Rβ1 and IL-12Rβ2 and
are found on activated T, NK and NKT cells.62,63 IL-12Rβ1 and IL-12Rβ2 occur on the
cell surface as oligomers. Oligomerization of the subunits is ligand independent.62 IL12Rβ1 binds the IL-12 p40 subunit whereas IL-12Rβ2 recognizes either the heterodimer
IL-12 or the IL-12 p35 subunit. Upon ligand binding, activation of Jak kinases occurs.
Tyk-2 is associated with IL-12Rβ1 and Jak-2 is associated with IL-12Rβ2 causing
phosphorylation of the IL-12 receptor. The phosphorylated receptor then phosphorylates
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STAT4 proteins. These phosphorylated STAT4 proteins then form homodimers and
translocate to the nucleus where they function as transcription factors (Figure 1.4).
IL-12 functions as a mediator between innate and adaptive immunity. At the
onset of an infection, IL-12, produced by activated macrophages, enhances the
cytotoxicity and proliferation of NK and T cells.64 IL-12 stimulates NK cytolytic activity
against NK-sensitive targets, NK-resistant targets, and antibody-coated targets. This
activity is more efficient than either IL-2 or the IFNs; requiring picomolar instead of
nanomolar concentrations.65 In developing Th1 cells, IL-12 leads to the upregulation of
IL-18 and adhesion molecules such as P- and E- selectin ligands allowing them to be
easily recruited to sites where an immune response is needed.66 IL-12 has been shown
consistently to have potent anti-tumor activity primarily through the activity of IFN-γ, the
activation of CD8+ T cells, and the inhibition of angiogenesis.67,68 In fact, it is thought
that IL-12 is responsible for the anticancer effects of Coley’s toxin, a mixture consisting
of killed bacterial species. In the treatment of inoperable sarcoma, Coley’s toxin
provided a 50% complete tumor regression at the time of therapy and more than 5-year
survival. Twenty percent of patients were cured and survived over 20 years. Although
Coley’s toxin was discovered over 100 years ago, modern immunotherapy trials have yet
to surpass these survival rates. Coley’s toxin can kill both developed tumors, through T
cells, and newly established tumors, through NK cells.69
Interferon-γ
IL-12 also works in conjunction with IL-2 as a potent inducer of several cytokines
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Figure 1.4 IL-12 Receptor. The IL-12 receptor uses a Jak/STAT signaling pathway.113
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but most importantly Interferon-γ (IFN-γ). IL-12 alone has been shown to increase the
production of the IFN-γ transcripts whereas IL-12 and IL-2 together increase IFN-γ
mRNA half-life.70 T lymphocytes and NK cells produce IFN-γ. At physiologic
conditions, IFN-γ is found as a homodimer held together by noncovalent bonds.71 The
IFN-γ receptor is ubiquitously expressed on all cells except erythrocytes and is made up
of two subunits: the high affinity receptor (IFN-γR1) and a low affinity receptor (IFNγR2).71,72 The IFN-γ homodimer binds to two IFN-γR1 chains that are preassembled with
IFN-γR2.73 The resulting receptor complex leads to transcriptional activity
predominantly through the JAK/ STAT pathway (Figure 1.5).74
IFN-γ has many important biological functions due to its control over a large
number of genes. IFN-γ is an important component of the cytokine cocktail that
promotes the development of helper T cells into Th1 cells while inhibiting the
development of Th2 cells, initiating cell-mediated immunity through the activation of
CD8+ T cells.75 B cells are also affected with an increase in isotype switching to IgG2a.76
IFN-γ increases monocyte microbicidal functions including secretion of hydrogen
peroxide, NO production, tryptophan depletion, and upregulation of lysosomal
enzymes.77,78 NO production also leads to local dilation of blood vessels causing
gathering of blood and eventually extravasation.79 It can also induce expression of
angiogenesis inhibitors, including IP10, that limit the size of tumor growth.80 It can alter
the proteasome to add variety and increase peptides available for MHC class I expression.
In addition, IFN-γ can increase the availability of the TAP transporter that helps provide
efficient peptide loading.79 IFN-γ can also arrest the cell cycle usually at the G1/S
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Figure 1.5 IFN- γ signal transduction. IFN-γ receptor is part of a Jak/STAT signaling cascade.74
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checkpoint. This is at least partially accomplished by inducing the transcription of p21
and p27 cyclin kinase inhibitors.81 Depending on the cell surface density of IFN-γR2,
apoptosis can be induced. In cells with high surface levels of IFN-γR2, there is rapid
activation of STAT1 and high levels of interferon regulatory factor-1 (IRF-1), which
triggers apoptosis through caspase 1.82
Cytokine Therapy
Cytokines are immunomodulatory molecules that play significant roles in
coordinating immune responses by signals through autocrine, paracrine, or endocrine
means. By increasing stimulatory cytokines, it may be possible to manipulate an immune
response. Many cytokines have been tested for anticancer abilities with the majority
proving to be toxic or ineffective. Interleukin 2 (IL-2) and interferon-alpha (IFN-α) have
been approved by the FDA to treat kidney cancer, leukemias, lymphomas, myelomas, and
melanoma.83 These drugs, however, do not specifically initiate an immune response
against tumor cells. For this reason, a large dose is required to get a clinically relevant
response. Many patients experience toxicity with high systemic doses of cytokines. To
ameliorate the requirement for high doses, cytokines have been engineered to specifically
target the tumor microenvironment.
Several methods have been employed to target IL-2 and IFN-α to tumor cells
using antibodies. By linking IL-2 to L19, an antibody specific to tumor neovasculature,
tumor size can be reduced significantly when compared to non-linked IL-2 and
gemcitabine, a first-line treatment for pancreatic cancer. This reduction was due in part
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to a 70 fold increase in NK cells to the tumor microenvironment.84 Similar results are
found when L19 is linked to IL-12 or TNF-α.85 IL-2 has also been linked to single-chain
T cell receptor that recognizes the aa264-272 peptide of human p53. p53, which is found
mutated in approximately half of all cancers, is not expressed on the surface of cells.
Peptides can, however, be displayed in the context of MHC class I molecules to be
recognized by T cells. This fusion protein significantly reduced A375 melanoma tumor
growth in nude mice.86
Another approach is to anchor cytokines to the surface of cancer cells by adding
glycosylphosphatidylinoditol (GPI). B16F0 melanoma cells transfected with GPI-IL-2,
when delivered intravenously to C57BL/6J mice, grew significantly slower than B16F0
cells and B16F0 cells transfected to secrete IL-2. The cells containing GPI-IL-2 were
also effective in preventing the growth of nearby B16F0 cells not expressing IL-2.87
Similar results were seen with a GPI-IL-12 construct. When GPI-IL-2 and GPI-IL-12
were coexpressed on the B16F0 cells, the survival of the tumor bearing animals was
significantly improved.88 Melanoma antigen-1 (MAGE-1)-expressing T24 tumor cells
have also been transfected with GPI-IL-2 for the production of tumor-derived exosomes
(TEXs). Preliminary in vitro studies show that dendritic cells pulsed with these TEXs
induce MAGE-1-specific CTLs more efficiently than dendritic cells pulsed with MAGE1 TEXs without GPI-IL-2.89
All of the above methods involve anchoring the cytokine in the tumor
microenvironment either through ligand interaction or GPI anchoring on the cell surface.
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Another method to reduce the amount of systemic cytokine required is to increase the
binding affinity of the cytokine to its receptor. The IL-2 high affinity quaternary receptor
complex is composed of IL-2, IL-2Rα (CD25), IL-2Rβ, and IL-2Rγ. All three receptors
are found in low densities on resting T cells making them relatively insensitive to IL-2
requiring high doses to initiate a response. When T cells are activated through the T cell
receptor, CD25 is upregulated.90 CD25 can then capture the IL-2 and present it to IL2Rβ and IL-2Rγ forming a high affinity receptor. Levin et al have used in vitro evolution
to produce an IL-2 “superkine” (also called super-2) that does not require CD25. The IL2 superkine has a higher binding affinity for IL-2Rβ due to a reduction in flexibility of a
helix in the IL-2Rβ binding site; this is similar to the conformational state found when
IL-2 is bound to CD25. The T cell expansion initiated by the IL-2 superkine is similar to
IL-2 but can progress at a much lower concentration reducing toxicity.91
NKG2D Ligands and IL-12 Function Together
IL-12 has been shown to be an effective preventative treatment for
methylcholanthrene (MCA) induced sarcoma with its effectiveness largely due to
NKG2D/NKG2D ligand binding. When mice were given IL-12 treatments prior to a
lethal dose of MCA, the mice were protected. However, when the IL-12 treatment was
given along with an anti-NKG2D mAb the protective effects were diminished
significantly.51 NKG2D engagement along with IL-12 therapy also causes an increase in
cytotoxicity and IFN-γ production in vitro.92 This could be caused by an increase in
expression of NKG2D ligands, TRAIL and perforin transcripts, and increased
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phosphorylation of STAT1, STAT4, and ERK1/2 in NK cells activated with IL-12 and
NKG2D engagement.93 Along with native NKG2D expression, the introduction of
soluble ULBP with IL-12 stimulated production of GM-CSF, TNF-β, and the CC
chemokine I-309 by NK cells in vitro whereas the use of either alone showed little effects
on these cytokines.94 This combination of IL-12 and NKG2D activity appears to be an
effective method for NK cell activation and target cell cytotoxicity.
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CHAPTER TWO

INTRODUCTION AND SPECIFIC AIMS

We hypothesize that a fusion protein containing an NKG2D ligand and IL-12 when
secreted from tumor cells into the tumor microenvironment will synergize the activation
of killer cells. The NKG2D ligand will perform two functions. First, it will activate
killer cells in the area using the NKG2D receptor causing an increase in killer cell
mediated cytotoxicity. Secondly, the NKG2D ligand will function as a carrier to deliver
IL-12 directly to the killer cells. When the NKG2D ligand binds to an NKG2D receptor
on the surface of a killer cell, the IL-12 will be held in close proximity to IL-12 receptors
on the same cell. The IL-12 will then also activate the killer cell leading to cytotoxicity
and proliferation. This dual activation of killer cells in the tumor microenvironment
should lead to increased tumor cell death and decrease in tumor volume (Figure 2.1).
Compared to traditional chemotherapy and radiation treatments, this novel fusion
protein has several benefits. This therapy takes advantage of the body’s natural defense
mechanisms that are already in place. Because this novel fusion protein activates killer
cells that are part of the innate immune system that does not require the use of tumor
specific antigens, this therapy should be easily translatable to many different tumor types.
Using gene therapy to deliver the fusion protein directly to the tumor cells will maintain a
high level of IL-12 in the tumor microenvironment while providing low systemic IL-12
levels, reducing toxicity.
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In our previous studies, we created a fusion gene consisting of the extracellular
domain of MULT1 and the transmembrane and intercellular domains of mouse Fas and
demonstrated that fusion protein MULT1E/mFasTI activates NK cells and induces
apoptosis of tumor cells expressing the protein in vitro and in vivo.59 The limitation of
fusion protein MULT1E/mFasTI is that it can only activate the NK cells that are engaged
with the tumor cells expressing the protein and it cannot activate other NK cells in the
tumor environment. The bifunctional protein created in this study, however, can provide
a local high dose of IL-12, which is able to activate NK cells in the local tumor
environment so that the therapy may be more effective.

	
  

27	
  

Figure 2.1 Summary of hypothesis
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We will test our hypothesis by pursuing the following specific aims:
1. The construction of an expression vector containing the MULT1E/mIL-12 fusion
gene The extracellular domain of MULT1 and the entire mIL-12 gene will be
cloned into the pcDNA3.1(+) expression vector. Expression vectors will also be
constructed to serve as controls: one with MULT1E alone and another with mIL12 alone.
2. Transfection and selection of stable clones expressing the MULT1E/mIL-12 fusion
protein The pcDNA3.1(+) expression vectors will be used to transfect TC-1
mouse lung carcinoma tumor cells using Lipofectamine. Stable clones will be
selected and characterized using RT-PCR, qRT-PCR, fluorescent microscopy,
immunofluorescence, and ELISA.
3. In vitro biological activity of the MULT1E/mIL-12 fusion protein Mouse NK cells
will be purified using negative selection from spleen cells with a MACS mouse
NK cell isolation kit. These NK cells will be co-cultured with clones expressing
the fusion protein. When NK cells are activated, they release a cocktail of
cytokines including IFN-γ. The amount of IFN-γ produced will be evaluated with
ELISA to determine the level of activation. To determine if there is a reduction in
tumor cells due to NK cytotoxicity, Promega’s CellTiter 96 AQueous will be used.
4. In vivo antitumor activity of MULT1E/mIL-12 fusion protein secreted by tumor
cells C57BL/6 mice will be injected intravenously with transfected tumor cells
expressing the MULT1E/mIL-12 fusion protein. After four weeks, tumor nodules
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will be counted and the weight of the lungs will be compared to determine if the
fusion protein has an effect on tumor volume.
5. The construction of an expression vector containing the MICA/IL-12 fusion gene
The extracellular domain of MICA and the entire IL-12 gene will be cloned into
the pcDNA3.1(+) expression vector. Expression vectors will also be constructed
to serve as controls: one with MICA alone and another with IL-12 alone.
6. Transfection and selection of stable clones expressing the MICA/IL-12 fusion
protein The pcDNA3.1(+) expression vectors will be used to transfect A549
human lung carcinoma tumor cells using Lipofectamine. Stable clones will be
selected and characterized using RT-PCR, immunofluorescence, and ELISA.
7. In vitro biological activity of the MICA/IL-12 fusion protein The human NK cell
line NK92 will be used to analyze the activating ability of the MICA/IL-12 fusion
protein. These NK92 cells will be co-cultured with clones expressing the fusion
protein. When NK92 cells are activated, they release a cocktail of cytokines
including IFN-γ. The amount of IFN-γ produced will be evaluated with ELISA to
determine the level of activation. To determine if there is a reduction in tumor
cells due to NK cytotoxicity, Promega’s CellTiter 96 AQueous will be used. NK92
cells will also be primed with supernatant collected from the A549 clones and cocultured with parental A549 cells to determine if priming can increase the killing
of cells that do not produce the protein. Lastly, human PBMCs will be isolated
from leukapheresis product using the Ficoll-Paque method and supernatant
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collected from the A549 clones will be used to activate them. Activation will be
determined using an IFN-γ ELISA. Promega’s CellTiter 96 AQueous will also be
used to determine if the protein can increase PBMC proliferation.

	
  

31	
  

CHAPTER THREE

MULT1E/mIL-12: A NOVEL BIFUNCTIONAL PROTEIN FOR NATURAL KILLER
CELL ACTIVATION1

Mrs. Ashlee Tietjea, Dr. Jinhua Lib, Dr. Xianzhong Yua, Dr. Yanzhang Weia
a

Department of Biological Sciences, Clemson University, Clemson, SC 29634

b

Department of Biotechnology, Greenville College of Technology, Greenville, SC 29601

Abstract
Natural killer (NK) cells have the potential to be effective killers of tumor cells.
They are governed by inhibitory and activating receptors like NKG2D, whose ligands are
normally upregulated in cells that are stressed, like cancer cells. Advanced cancer cells,
however, have ways to reduce these ligands’ expression, leaving them less detectable by
NK cells. Along with these receptors, NK cells also require activating cytokines, like
interleukin 12 (IL-12). The goal of this study is to develop a novel bifunctional fusion
protein for enhanced NK cell activation. The proposed protein combines the extracellular
domain of the NKG2D ligand Mouse UL-16-binding protein-like transcript 1 (MULT1E)
and mouse IL-12 (mIL-12). It is hypothesized that when expressed by tumor cells, the
protein will activate NK and other killer cells using the NKG2D receptor, and deliver
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  Cited from: Gene Ther. 21, 468–475 (2014) with modifications
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mIL-12 to the NK cells where it can interact with the IL-12R and enhance cytotoxicity.
The fusion protein, when expressed by engineered tumor cells, indeed activated NK cells
in vitro as assayed by increased production of interferon-γ and cytotoxicity and
significantly reduced tumor growth in vivo. Although the study is preliminary, the data
suggest that the MULT1E/mIL-12 bifunctional fusion protein is an effective activator of
NK cells for cancer treatment.

Keywords: NK cells, NKG2D, IL-12, MULT, cancer, fusion protein
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Introduction
Natural killer (NK) cells are part of the innate immune system and are one of the
primary cell types involved in immunosurveillance. At the onset of neoplastic growth,
damaged cells upregulate surface antigens, some of which are ligands for NK cell
activating receptors, including NKG2D ligands. Once NK cells are activated, cytotoxic
granules are exocytosed into the extracellular space between the NK cell and the target
cell.19 As the cancer progresses, however, tumor cells have found ways to downregulate
surface NKG2D ligands. It has been shown that the extracellular domains of MHC classI related molecule A (MICA), a human NKG2D ligand, can be shed by tumor cells by
proteolytic cleavages, thus preventing activation of cytotoxic immune cells.52 The
immune system may also aid in selecting against tumor cells that maintain NKG2D
ligand expression.
Mouse UL-16 binding protein-like transcript 1 (MULT1) is an NKG2D ligand
with a protein sequence similar to human UL16-binding protein 3.41 The 37.1 KD
protein contains two major histocompatibility class I-like α domains. Unlike ULBP or
the RAE1 family proteins that are anchored to the cell membrane by
glycosylphosphatidylinositol, MULT1 is a type I transmembrane protein with both a
transmembrane and a cytoplasmic domain. Unlike other mouse ligands for NKG2D,
which are expressed and only upregulated on diseased cells, MULT1 transcripts are
detectable in many normal tissues including thymus, spleen, lymph nodes, liver, heart,
and lung.42 No surface expression of MULT1 is detected, however, when stained with
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NKG2D tetramers suggesting that MULT1 is regulated post-transcriptionally. Nice et al
showed that MULT1 is regulated posttranslationally through ubiquitination dependent on
lysines in its cytoplasmic tail and lysosmal degradation under normal conditions.43
Degradation and ubiquitination of MULT1 can be decreased by heat shock or ultraviolet
irradiation leading to higher surface expression. The same results were not seen with
ionizing radiation, 5-FU, cisplatin, or mitomycin C.43 Due to these properties, MULT1
serves as an excellent target of anti-cancer immunotherapies.
Interleukin 12 (IL-12), also known as NK cell stimulatory factor 2, is an activator
and initiator of NK cell proliferation. This activity is more efficient than either IL-2 or
the interferons (IFNs) requiring picomolar instead of nanomolar concentrations.65 In fact,
NK cells expressing an IL-12 and mouse sonic hedgehog C-terminal domain fusion gene
showed reduced (>10 fold) dependency on IL-2 and a significantly prolonged survival
time for tumor bearing mice receiving an intravenous injection of these cells.95 IL-12 has
been shown consistently to have potent anti-tumor activity primarily through the activity
of IFN-γ, the activation of CD8+ T cells, and the inhibition of angiogenesis.67,68
We hypothesize that a bifunctional fusion protein containing the NKG2D ligand
MULT1 and mouse IL-12 (mIL-12) will synergize the activation of NK cells and other
NKG2D-expressing killer cells. The proposed fusion protein combines the extracellular
domain of MULT1 (MULT1E) and mIL-12. When delivered to the tumor
microenvironment, NK cells and other NKG2D-expressing killer cells will be activated
simultaneously through the MULT1/NKG2D pathway and the IL-12/IL-12R pathway. In
addition, MULT1E will also function as a carrier to deliver mIL-12 directly to the killer
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cells. When the MULT1E domain binds to an NKG2D receptor on the surface of an NK
cell, the mIL-12 will be held in close proximity to IL-12 receptors on the same cell,
which will maintain a high level of mIL-12 in the tumor microenvironment while
providing low systemic mIL-12 levels and reduced toxicity
The hypotheses were first examined by transfecting the fusion gene into the
mouse lung carcinoma cell line TC-1. Stable clones of tumor cells expressing the fusion
protein and control IL-12 or MULT1E proteins were evaluated in a series of in vitro
assays. Preliminary in vivo studies showed that the dual activation of NK cells by the
fusion protein in the tumor microenvironment led to increased tumor cell death and a
decrease in tumor volume.
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Results
Transfection and selection of stable clones expressing the MULT1E/mIL-12 fusion
protein
TC-1 cells were transfected with pCDNA3.1(+)MULT1E/mIL-12/Zeo (Figure
3.1a) using Lipofectamine. Clones that were zeocin resistant were selected and labeled as
M-IL/4, M-IL/5 and M-IL/8. TC-1 cells were also transfected with
pcDNA3.1(+)MULT1E/Zeo or pcDNA3.1(+)mIL-12/Zeo to generate control clones
(MULT/6 and IL/3) that produce either MULT1E or mIL-12, respectively. An in vitro
cell growth study shows that all clones grow at a similar rate (data not shown).
The fusion protein expression was first examined by reverse transcription-PCR
(RT-PCR) on total RNA samples collected from the clones using three pairs of primers.
The first pair was specific to a 1.6-kb portion of the MULT1E/mIL-12 fusion gene
containing 57 bp of MULT1E, the (GGGS)3 linker and the 1545 bp of mIL-12. The
second pair amplified a 439-bp sequence near the 3′ end of mIL-12. The third pair
amplified the entire 633 bp MULT1E sequence. Only clones M-IL/4, M-IL/5 and M-IL/8
contain mRNA transcripts for the MULT1E/mIL-12 fusion gene (Figure 3.1b). As
expected, the fusion gene clones, along with the IL/3 clone contain mRNA transcripts for
the 3′ segment of mIL-12 (Figure 3.1c). All cells, including the TC-1 control cells and
IL/3, contain mRNA transcripts for MULT1E (Figure 3.1d). Although quantification is
not accurate with RT-PCR, the densitometry measurements show that Clone M-IL/4
produced more transcripts of the fusion gene than Clones M-IL/5, which produced more
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Figure 3.1. Plasmid pcDNA3.1(+)MULT1E/mIL-12/Zeo. Mouse interleukin 12 (mIL-12) was cloned from
pORF-mIL-12 and a (GGGS)3 linker was added using PCR. mIL-12 was then inserted into the plasmid
pcDNA3.1(+)MULT1E/Neo to form the plasmid pcDNA3.1(+)MULT1E/mIL-12/Neo. The fusion gene
MULT1E/mIL-12 was then cut from the plasmid and inserted into pcDNA3.1(+)Zeo to form
pcDNA3.1(+)MULT1E/mIL-12/Zeo (A). RT-PCR analysis of clones with transgenes. Total RNAs were
isolated from each clone using primers to amplify a 1.6kb portion of the MULT1E/mIL-12 fusion gene
containing 57 bp of MULT1E, the (GGGS)3 linker, and 1545 bp of mIL-12 (B), a 439 bp sequence near the
3’ end of mIL-12 (C), or the entire 633 bp MULT1E sequence (D). Densitometry measurements of the bands
for the three gene expression was performed and presented (E). All reactions included the β-actin
housekeeping gene as controls (488 bp).
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transcript than M-IL/8 (Figures 3.1b and e). It cannot be determined with RT-PCR if
there is a difference between the background MULT1E transcription level found in the
TC-1 control cells and the MULT1E transcription levels of the clones. To determine this,
quantitative RT-PCR (qRT-PCR) was employed. Qiagen’s QuantiTect SYBR Green RTPCR kit was used to find relative quantification of' MULT1E mRNA transcripts using the
housekeeping gene β-actin. The manufacturer’s directions were followed using 500 ng
total RNA and primers to amplify an 80 bp sequence at the 3′ end of MULT1E. The M-IL
clones each show a significant increase in MULT1E mRNA transcription with M-IL/4
having the highest level and M-IL/8 having the lowest level (Table 3.1). This is
consistent with the RT-PCR results above for the MULT1E/mIL-12 fusion gene. The
IL/3 clone, however, also has a statistically significant increase in MULT1E mRNA
transcription. To further confirm the transgene expression, cells of these clones were
fixed, permeabilized and stained with both PE rat anti-mIL-12 and the chimeric protein
mNKG2D/hIgG1 followed by fluorescein isothiocyanate antimouse NKG2D. In
consistence with the PCR results, clone M-IL/4 expressed the highest levels of the fusion
protein and M-IL/5 expressed intermediate levels of the fusion protein, whereas the
fusion protein expression by clone M-IL/8 was not detectable (Figure 3.2). As expected,
clone IL/3 only expressed mIL-12 and clone MULT/6 only expressed MULT1E (Figure
3.2)
The secretion of the transgene products was detected with a sandwich ELISA with
anti-mouse MULT1 as the capturing antibody and anti-mIL-12 conjugated to PE as the
detecting antibody. Consistent with RT-PCR data and fluorescent microscopy, clones
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Table 3.1. qRT-PCR analysis of clones for MULT-1 gene expression. Qiagen’s QuantiTect SYBR Green RTPCR kit was used to find relative quantification of MULT1E mRNA transcripts using the housekeeping gene
B-actin as a control. Primers were used to amplify an 80bp sequence at the 3’ end of MULT1E. The data
was analyzed using the comparative CT method using the formula 2-ΔΔCT.99

Clone

	
  

Fold difference from TC-1 control

p-value

M-IL/4

20

p<0.001

M-IL/5

8

p<0.01

M-IL/8

4

p<0.05

IL/3

16

p<0.001
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Figure 3.2. Fluorescent microscopy analysis of clones with transgenes. To detect the production of the
transgene products by the selected clones, cells were fixed, permeabilized, and stained with rat anti-mouse
IL-12 (p40/p70) antibody conjugated with PE and the chimeric protein mNKG2D/hIgG1 for 1 hour at room
temperature followed by staining with anti-mouse NKG2D conjugated with FITC.
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M-IL/4 and M-IL/5 produced significant levels of the MULT1E/ mIL-12 fusion protein
and successfully released it into the supernatant with M-IL/4 producing more than MIL/5. Clones M-IL/8, IL/3 and MULT/6 did not produce detectable amounts of
the fusion protein (Figure 3.3a). ELISA was also performed to detect mIL-12 or
MULT1E separately. Clones M-IL/4 and IL/3 both produced similar amounts of mIL-12
and, therefore, IL/3 was used as the mIL-12 control clone for later studies. Compared
with clone M-IL/4, clone M-IL/5 produced lower levels of mIL-12. In concurrence with
the fluorescent microscopy data and the MULT1E/mIL-12 ELISA, clones M-IL/8 and
MULT/6 did not produce detectable levels of mIL-12 (Figure 3.3b). The secreted form of
MULT1E was detected at significant levels in clones M-IL/4, M-IL/5 and MULT/6
(Figure 3.3c). MULT/6 produces similar amounts of MULT1E as M-IL/5 and will be
used as the MULT1 control.
In vitro biological activity of the MULT1E/mIL-12 fusion protein
Mouse NK cells were purified using negative selection from spleen cells and
cocultured with clones expressing the fusion protein, mIL-12 or MULT1E and an IFN-γ
ELISA was used to detect NK cell activation (Figure 3.3d). Clones M-IL/4, M-IL/5 and
IL/3 all activated NK cells to produce significantly higher levels of IFN-γ than the control
TC-1 cells. Clone M-IL/5 stimulated production of significantly more IFN-γ than clones
M-IL/4 and IL/3 (P<0.001). Clone M-IL/4 stimulated production of similar levels of IFNγ as clone IL/3. Neither clone M-IL/8 nor clone MULT/6 stimulated significant
production of IFN-γ by NK cells. In order to determine whether the activated NK cells
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Figure 3.3. Detection of secreted transgene products. Supernatant from each clone was collected for ELISA
analysis. The fusion gene was detected using an antibody to MULT1 as the capturing antibody and antimIL-12 antibody conjugated with PE as the detecting antibody (A). mIL-12 was detected using an mIL-12
p70 Ready-SET-Go! ELISA kit following the manufacturer’s directions (B). MULT1 was detected using an
antibody to MULT1 as the capturing antibody and rmNKG2D was used as the detecting reagent followed by
an anti-mNKG2D antibody conjugated with FITC (C). Clones were compared using a two-way ANOVA
with Tukey’s post-test. NK cell activation. Fresh mNK cells were cocultures with different clones in a 96
well plate at a ratio of 3:1 and incubated for 48 hours. After the incubation, media was removed and
analyzed for the presence of IFN-γ using ELISA (D). The NK cells’ cytotoxicity was determined by
measuring the proliferation of the tumor cells using Promega’s CellTiter 96 AQ ueous nonRadioactive cell
proliferation assay following the manufacturer’s instructions (E). Clones were compared using a one-way
ANOVA with Tukey’s post-test for panel A and student t test for panel B. *p<0.05, **p<0.01, and
***p<0.001.
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can kill tumor cells expressing different transgene products, tumor cell proliferation was
also measured using the MTS assay. NK cells killed significantly more tumor cells of
clone M-IL/5 and clone MULT/6 (Figure 3.3e).
In vivo antitumor activity of tumor cells producing MULT1E/mIL-12 fusion protein
In order to determine whether the fusion protein can inhibit tumor growth in vivo,
tumor cells expressing the fusion proteins, mIL-12 or MULT1E were intravenously
injected into female C57BL/6J mice, respectively, and after 4 weeks, the mice were
euthanized and their lungs were excised (Figure 3.4a). Lung volume was measured and
the number of surface tumor nodules was counted. When compared with the control TC-1
cells, all the clones generated significantly fewer tumor nodules (Figure 3.4b). Among
the clones, M- IL/4 did not grow any lung surface nodules, whereas clone M-IL/5 grew
significantly fewer nodules than clone M-IL/8 or clone IL/3. Lung weight was also
measured to include any tumors growing within the lungs (Figure 3.4c). The total lung
weights of clones M-IL/4 and M-IL/5 are significantly lighter than clone M-IL/8.
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Figure 3.4. In vivo antitumor activity of MULT1E/mIL-12 fusion protein. C57BL/6 female mice were injected
intravenously with 1-2x105 cells in 0.5ml HBSS from each clone with TC-1 as a control. Four weeks later, the
mice were euthanized and the lungs were excised (A) and fixed with 4% paraformaldehyde. The tumor
nodules on each lung were counted using a dissecting microscope (B) and the tumor weight was recorded (C).
Clones were compared using a one-way ANOVA with Tukey’s post-test. *p<0.05, **p<0.01, and ***p<0.001.
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Discussion
Because NK cells have an important role in tumor immunosurveilance, many
strategies have been employed to harness their ability to prevent neoplastic growth. Most
of these strategies failed to provide significant clinical benefit or the toxicity experienced
by patients outweighed any benefit.96 In this study, we developed a bifunctional fusion
protein, MULT1E/mIL-12, and hypothesized that it would effectively activate NK cells
and other NKG2D-expressing killer cells in the tumor environment.

Screening for intracellular protein by fluorescent microscopy indicates that clones
M-IL/4, M-IL/5 and M-IL/8 express varied levels of the fusion protein with clone M-IL/4
producing the most and clone M-IL/8 producing the least (Figure 3.2). RT-PCR and qRTPCR confirm that this difference originates at the transcription level (Figures 3.1b–e and
Table 3.1). There is also a background level of endogenous MULT1 transcription found
in all clones. This background MULT1 transcription level is significantly increased in
clone IL/3 (Table 3.1). This could be a result of the stress of transfection. Previous
studies have shown that MULT1 is regulated post-transcriptionally; therefore, an increase
in mRNA expression might not necessarily correlate with an increase in protein
expression.43
It is important to demonstrate that the fusion protein is being released from the
cell so it can interact with NK cells in the tumor microenvironment. To test this,
supernatant was collected and screened using ELISA. The protein secretion data confirm
that the protein being produced within the cell is also being released from the cell into the
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supernatant (Figures 3.3a–c). A significant difference in the fusion protein expressed by
clone M-IL/5 was observed when using the two different ELISA assays (Figures 3.3a
and b). We suspect that the difference is due to the capture antibody for MULT1 in
Figure 3.3a is not sufficient to detect all the proteins in the supernatants, whereas the IL12 ELISA in Figure 3.3b is able to catch more, if not all, of the fusion proteins in the
supernatants. ELISA data also confirm that although there is an increase in MULT1E
transcripts in clone IL/3, there is no significant increase in the secreted form of MULT1E
(Figure 3.3c). Q4
To determine whether the fusion protein MULT1E/mIL-12 has enhanced ability
to activate NK cells in vitro, freshly isolated NK cells were cocultured with clones
expressing the transgenes. The amount of IFN-γ produced by NK cells was evaluated
with ELISA to determine the level of NK cell activation. Clones M-IL/4, M-IL/5 and
IL/3 produced significantly higher levels of IFN-γ than the control TC-1 cells. It is
interesting to note that although clone M-IL/5 expressed lower levels of the fusion
protein than clone M-IL/4 (Figure 3.2 and Figures 3.3a–c), it stimulated production of
significantly more IFN-γ than clones M-IL/4 and IL/3 (Figure 3.3d). Further studies are
needed to understand why this happened. Clone M-IL/4 stimulated production of similar
levels of IFN-γ as clone IL/3, which is expected because they both have similar mIL-12
expression levels as shown in the mIL-12 ELISA (Figure 3.3b). Neither clone M-IL/8 nor
clone MULT/6 stimulated significant production of IFN-γ. This is expected because the
mIL-12 pathway, not MULT, is responsible for initiating the production of IFN-γ.67,68
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To determine whether the fusion protein has the ability to enhance NK cell target
cell killing activity, Promega’s CellTiter 96 AQueous nonRadioactive cell proliferation
assay was used to measure the amount of target cells remaining after incubating with NK
cells. The proliferation of clone M-IL/5 showed a significant decrease when compared
with the clone that only produces mIL-12 (IL/3; Figure 3.3e). The decrease seen in clone
M-IL/5 is also similar to the decrease seen in the MULT1E control clone (MULT/6). This
suggests that although the IL/3 clone is able to increase the production of IFN-γ by NK
cells, the addition of the MULT1E increases the cytotoxicity. This indicates that the mIL12 moiety is responsible for initiating IFN-γ production and the MULT1E is responsible
for activating NK cell-mediated cytotoxicity. It is expected that the in vivo increase in
IFN-γ production will be able to modify other cell types not present in the in vitro model
to aid in tumor cell killing. This should amplify the activity of the MULT1E/mIL-12
fusion protein.
To determine whether MULT1E/mIL-12 can activate NK cells to kill more tumor
cells in vivo, tumor cells expressing the fusion protein were intravenously injected into
mice and tumor burden was compared with mice receiving the parental tumor cells. After
4 weeks, the mice were euthanized and their lungs were excised. Lung volume was
measured and the number of surface nodules was counted. There was a significant
decrease in tumor count seen with all clones when compared with the parental TC-1 cells
(Figure 3.4a). Although tumor count among the clones is very low, there appears to be a
dose-dependent relationship in the MULT1E/mIL-12 clones. The higher expression of
MULT1E/mIL-12 of clone M-IL/4 also seems to be more effective than the mIL-12 alone
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(clone IL/3; Figure 3.4b). High expression of MULT1E/IL-12 fusion protein (clones MIL/4 and M-IL/5) also showed a decrease in total lung weight compared with low fusion
protein expression (clone M-IL/8; Figure 3.4c). It is also interesting to note that although
clone IL/3 generated more tumor nodules on lungs (Figure 3.4b) than clone M-IL/8, the
average lung weight of clone IL/3 is slightly lower than clone M-IL/8 (Figure 3.4c). We
speculate that clone IL/3 tumors are smaller than clone M-IL/8 tumors, suggesting a
possibility that NK cells or other NKG2D-expressing cells are activated after the tumor
cells metastasized to the lung.
An interesting phenomenon observed in this report is the inconsistency of in vitro
expression, in vitro NK cell activation and in vivo tumor inhibition between clones MIL/4 and M-IL/5. Clone M-IL/4 expressed higher levels of fusion protein (Figure 3.3a),
whereas clone M-IL/5 stimulated more IFN-γ by NK cells and inhibited more tumor
growth in vitro (Figures 3.3d and e). In contrast, clone M-IL/4 inhibited more tumor
growth than clone M-IL/5 in vivo. Although more studies are needed to clarify this
inconsistency, it can be speculated that the NK cell activation and its anti-tumor
mechanisms are different between in vitro and in vivo.
Two questions remain to be answered. First, are NK cells activated by the fusion
protein in vivo? To answer this question, cells from different clones will be inoculated in
to NK cell-deficient beige KO mice (C57BL/6J-Lystobg-J/J)97 and tumor development
will be monitored. We speculate that the tumors will grow faster in beige mice when
compared with regular C57 BL/6J mice. Second, these pulmonary metastasis data cannot
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differentiate whether the fusion protein prevents implantation of the tumor cells by
causing NK cells to destroy them en route or if NK cells destroy the tumor cells postimplantation. To answer this question, we plan to develop a lentiviral vector or an
adenoviral vector to deliver this fusion gene directly to established tumors. This will also
provide pre-clinical data as lentiviral vectors and adenoviral vectors are already approved
for clinical trials.98 We will also investigate the possibility of using nanoparticles to
deliver the fusion gene specifically to tumors. When the efficacy of the fusion gene and
its delivery method is confirmed in animal models, this therapy could easily be converted
for use in human immunotherapy by replacing MULT1E with major histocompatibility
complex class I-related molecule A, a human NKG2D ligand, and mIL-12 with hIL-12.
Another concern is the side effects of using this bifunctional protein. Although we did not
observe any side effects in the current study, it should be a focus in the future in vivo
studies, especially when viral vectors or nanoparticles are used to deliver the fusion gene
into tumors. One of the key concerns will be how to make sure the gene is delivered into
tumor cells specifically, but not into other healthy cells because if the gene is expressed
by healthy cells, the fusion protein may activate NK cells in healthy tissues and cause off
target effects.
In our previous studies, we created a fusion gene consisting of the extracellular
domain of MULT1 and the transmembrane and introcellular domains of mouse Fas and
demonstrated that fusion protein MULT1E/mFasTI activates NK cells and induces
apoptosis of tumor cells expressing the protein in vitro and in vivo.59 The limitation of
fusion protein MULT1E/mFasTI is that it can only activate the NK cells that are engaged
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with the tumor cells expressing the protein and it cannot activate other NK cells in the
tumor environment. The bifunctional protein created in this study, however, can provide
a local high dose of IL-12, which is able to activate NK cells in the local tumor
environment so that the therapy may be more effective.
In conclusion, a fusion protein containing the extracellular domain of the NKG2D
ligand MULT1 and mIL-12 was successfully created and can be stably expressed by TC1 tumor cells. The fusion protein can increase the production of IFN-γ by NK cells in
vitro and also increase the cytotoxicity when compared with clones expressing only mIL12. Preliminary studies show that the anti-tumor activity of the MULT1E/mIL-12 fusion
protein was more effective in vivo than clones expressing mIL-12 alone when the cells
were introduced intravenously. The MULT1E/mIL-12 fusion protein may be a novel and
effective anti-tumor therapy.
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Materials and Methods
Cells and animals
The mouse lung carcinoma cell line TC-1 (ATCC no. CRL-2785) was cultured in
RPMI 1640 medium containing 10% fetal bovine serum and 100 µg/ml gentamicin at
37oC with 5% CO2. Freshly isolated NK cells were maintained in RPMI 1640 containing
10%FBS, 50 µM β-mercaptoethanol, 2 mM glutamine, and 10 ml/L 100 x nonessential
amino acids at 37oC with 5% CO2.
C57BL/6J female mice were housed in a pathogen-free animal facility. The animal
experiments were carried out in accordance with the Guidelines for the Care and Use of
Laboratory Animals (NIH Publication number 85–23) and the institutional guidelines.
Construction of pcDNA3.1(+)MULT1E/mIL-12/Neo Vector
The mIL-12 sequence was amplified from pORF-mIL-12 (InvivoGen, San Diego,
CA) using the 5’ primer CGCGGATCCGGTGGTGGTTCTGGTGGTGGTTCTGGTGG
TGGTTCTAGGGTCATTCCAGTCTCTGGACCTGCCAGGTGTCTTAGCC and the 3’
primer CCTCGAGCTAGGATCGGACCCTGCAGGG. The 5’ primer contains a
restriction cut site for BamHI and a (GGGS)3 linker to separate the two functional
domains of the fusion protein. The 3’ primer contains the restriction cut site for XhoI.
The signal sequence and start codon were not amplified. PCR was performed to amplify
mIL-12 using Phusion High-Fidelity DNA Polymerase (New England BioLabs, Ipswich,
MA, USA). The fragment was excised and gel purified using a gel purification kit
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(Qiagen, Valencia, CA, USA). Double enzyme digestion was performed on the purified
fragment using BamHI and XhoI. The plasmid pcDNA3.1(+)MULT1E/Neo, created
earlier in our lab,59 was digested with BamHI and XhoI allowing for the insertion of mIL12 directly downstream of MULT1E in frame. The linearized plasmid was excised and
gel purified using a gel purification kit (Qiagen, Valencia, CA, USA). The enzyme
digested mIL-12 PCR fragment was then ligated to the pcDNA3.1(+)MULT1E/Neo
creating the new plasmid pcDNA3.1(+)MULT1E/mIL-12/Neo (Figure 3.1A). The
sequence was confirmed using DNA sequencing.
Construction of pcDNA3.1(+) MULT1E/mIL-12/Zeo Vector
To construct the zeocin resistant vector necessary to transfect TC-1 cells,
pcDNA3.1(+)MULT1E/mIL-12/Neo and pcDNA3.1(+)Zeo (Invitrogen, Carlsbad, CA,
USA) were digested with HindIII and XhoI. The linear vector of pcDNA3.1(+)Zeo and
fragments containing MULT1E/mIL-12 from pcDNA3.1(+) MULT1E/mIL-12/Neo were
then excised and gel purified using a gel purification kit (Qiagen, Valencia, CA, USA).
They were then ligated creating the plasmid pcDNA3.1(+)MULT1E/mIL-12/Zeo
Construction of pcDNA3.1(+)mIL-12/Zeo Vector
To make a control mIL-12 vector, the mIL-12 sequence was again amplified from
pORF-mIL-12 (InvivoGen, San Diego, CA). However, the start codon and signal
sequence need to be reserved, so a different 5’ primer (CCAAGCTTCCATGGGTCAAT
CACGCTACCTCC) with a HindIII cut site at the 5’ end was used. The original 3’
primer with the restriction cut site for XhoI was also used. PCR was performed to
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amplify mIL-12 using Phusion High-Fidelity DNA Polymerase (New England BioLabs,
Ipswich, MA, USA). The fragment was excised and gel purified using a gel purification
kit (Qiagen, Valencia, CA, USA). Double enzyme digestion was performed on the
purified fragment using HindIII and XhoI.
pcDNA3.1(+)Zeo was digested with HindIII and XhoI allowing for the insertion of
mIL-12. The fragment was excised and gel purified using a gel purification kit (Qiagen,
Valencia, CA, USA). The mIL-12 sequence was then ligated to pcDNA3.1(+)Zeo
(Invitrogen, Carlsbad, CA, USA) creating the new plasmid pcDNA3.1(+)mIL-12/Zeo.
The sequence was confirmed using DNA sequencing.
Construction of pcDNA3.1(+)MULT1ES/Zeo
To make a control MULT1E vector encoding secretable MULT1E, the MULT1E
sequence was amplified from pcDNA3.1(+)MULT1E/Neo. The 5’ primer (CCCAAGCT
TATGGAGCTGACTGCCAGTAACAAGGTCC) included a restriction site for HindIII
and the 3’ primer (CCCTCGAGCTAGGTACTGAA) included a stop codon and the
restriction site for XhoI. PCR was performed to amplify MULT1E using Phusion HighFidelity DNA Polymerase (New England BioLabs, Ipswich, MA, USA). The fragment
was excised and gel purified using a gel purification kit (Qiagen, Valencia, CA, USA).
Double enzyme digestion was performed on the purified fragment using HindIII and
XhoI.
pcDNA3.1(+)Zeo (Invitrogen, Carlsbad, CA, USA) was digested with HindIII and
XhoI allowing for the insertion of MULT1E. The fragment was excised and gel purified
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using a gel purification kit (Qiagen, Valencia, CA, USA). The MULT1E sequence was
then ligated to the pcDNA3.1(+)Zeo creating the new plasmid
pcDNA3.1(+)MULT1E/Zeo. The sequence was confirmed using DNA sequencing.
Cell transfection
TC-1 cells were transfected with either pcDNA3.1(+)MULT1E/mIL-12/Zeo,
pcDNA3.1(+)mIL-12/Zeo, or pcDNA3.1(+)MULT1E/Zeo using Lipofectamine
(Invitrogen, Carlsbad, CA, USA) as directed by the manufacturer. To obtain stable
clones, the transfected TC-1 cells were cultured in medium containing 200 µg/ml zeocin.
Drug-resistant clones were collected and subcultured in the presence of the appropriate
drug.
Proliferation Assay
To determine if the selected clones grow at the same rate as the untransfected
cells, cells were counted every day for 5 days. On day one, 0.04x106 cells were plated on
12 well plates in triplicates. At each time point, 3 wells of each clone were trypsinized
and counted using a hemocytometer. This test was preformed twice to obtain 6
replicates. Clones were compared using a two-way ANOVA with Tukey’s post-test.
RT-PCR
Total RNA was extracted from each clone using an RNeasy Plus Mini Kit (Qiagen,
Valencia, CA, USA) following the manufacturer’s directions. cDNA was produced from
2ug of the total RNA using the QuantiTect RT (QIAgen, Valencia, CA, USA) following
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the manufacturer’s directions. Four microliters of the product was then added to a PCR
reaction containing primers to amplify a 1.6kb portion of the MULT1E/mIL-12 fusion
gene containing 57 bp of MULT1E, the (GGGS)3 linker, and 1545 bp of mIL-12. A
Phusion High-Fidelity DNA Polymerase kit (New England BioLabs, Ipswich, MA, USA)
was used with the 5’ primer GATGAGCTCATGTTGCACTG and the 3’ primer CATTC
CCGCCTTTGCATTGGAC. Similar reactions were carried out to amplify a 439 bp
sequence near the 3’ end of mIL-12 (using the 5’ primer GCAGTGACATGTGGAATG
GC and the 3’ primer CATTCCCGCCTTTGCATTGGAC) and the entire 633 bp
MULT1E sequence (using the 5’ primer CCCAAGCTTATGGAGCTGACTGCCAGTA
ACAAGGTCC and the 3’ primer CCCTCGAGCTAGGTACTGAA). All reactions
included the β-actin housekeeping gene. The density of the DNA bands were quantified
using the built-in software from the Fotodyne gel doc system, FOTO/Analyst FX.
qRT-PCR
Qiagen’s QuantiTect SYBR Green RT-PCR kit was used to find relative
quantification of MULT1E mRNA transcripts using the housekeeping gene β-actin. The
manufacturer’s directions were followed using 500ng total RNA, the 5’ primer GACTGC
AGGACCTGGCTTGATGAGC, and the 3’ primer CCCTCGAGCTAGGTACTGAA to
amplify an 80bp sequence at the 3’ end of MULT1E. The reaction was carried out in a
Mastercycler Ep Realplex (Eppendorf, Hamburg, Germany) and analyzed using the
comparative CT method using the formula 2-ΔΔCT.99
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Fluorescent Microscopy
To detect the production of the transgene products by the selected clones, 3x104
cells of each clone were plated in 96 well plates and incubated at 37oC overnight. After
the incubation time, the media was removed and the cells were washed twice with
staining buffer (PBS, 0.1%BSA, and 0.1% sodium azide). Cells were fixed by incubating
cells for 30 min at 4oC with fixation buffer (BD Pharmingen, San Jose, CA, USA). The
fixation buffer was then removed and the cells were washed with pre-warmed
permeabilization buffer (BD Pharmingen, San Jose, CA, USA). The cells were then
incubated with permeabilization buffer for 30 min at 37oC. After washing twice with
staining buffer, the cells were stained with PE rat anti-mouse IL-12 (p40/p70) (2.5µg/ml)
(BD Pharmingen, San Jose, CA, USA) and the chimeric protein mNKG2D/hIgG1
(1µg/ml) (R&D Systems, Minneapolis, MN, USA) for 1 hour at room temperature. The
cells were then washed three times with staining buffer. FITC anti-mouse NKG2D (2.5
µg/ml) (BioLegend, San Diego, CA, USA) was then added and incubated for an hour in
the dark. The cells were then washed five times with staining buffer and observed with
an Olympus 1x70 fluorescent microscope.
Detection of Secreted Protein
Cells of different clones were plated at 2x106 cells in 6 well plates with normal
growth media on day one. On day two, the media was removed, the cells were rinsed
with PBS, and serum free RPMI was added. On day three, the serum free RPMI was
removed and centrifuged at 1000g for 15 min. The supernatant was then tested using an

	
  

57	
  

appropriate immunofluorescence or ELISA protocol.
To detect the presence of MULT1E/mIL-12, 96 well plates were coated with 2
µg/ml mouse MULT1 mAb (Clone 237104) Rat IgG2A (R&D Systems, Minneapolis,
MN, USA) in carbonate coating buffer and incubated overnight at 4oC. The plates were
rinsed with PBS and blocked with 10% FBS for 1.5 hours. After washing three times
with PBS, 100µl of the cell supernatant was added to the plate in triplicates. The samples
were incubated at room temperature for 3 hours. After removing the samples and
washing the plates three times with PBS, 1 µg/ml PE rat anti-mouse IL-12 (p40/p70) (BD
Pharmingen, San Jose, CA, USA) in blocking solution was added to the plates. The
plates were then incubated for 1.5 hours at room temperature. After washing five times
with PBS, the plates were read with a SpectraMax Gemini XS using SOFTMax Pro 3.1.2
software (Molecular Devices, Sunnyvale, CA, USA). Clones were compared using a
one-way ANOVA with Tukey’s post-test.
To detect the presence of MULT1E, 96 well plates were coated with 2 µg/ml
mouse MULT1 mAb (Clone 237104) Rat IgG2A (R&D Systems, Minneapolis, MN,
USA) in carbonate coating buffer and incubated overnight at 4oC. The plates were rinsed
with PBS and blocked with 10% FBS for 1.5 hours. After washing three times with PBS,
100µl of the cell supernatant was added to the plate in triplicates. The samples were
incubated at room temperature for 3 hours. After removing the samples and washing the
plates three times with PBS, 1 µg/ml mNKG2D/hIgG1 chimeric protein (BD Pharmingen,
San Jose, CA, USA) in blocking solution was added to the plates. The plates were then
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incubated for 1.5 hours at room temperature. After washing five times with PBS, 1ug/ml
FITC mouse anti-hIgG (BD Pharmingen, San Jose, CA, USA) in blocking solution was
added to the plates and incubated for 1.5 hours at room temperature. After washing five
more times with PBS, plates were read with a SpectraMax Gemini XS using SOFTMax
Pro 3.1.2 software (Molecular Devices, Sunnyvale, CA, USA). Clones were compared
using a one-way ANOVA with Tukey’s post-test.
To detect the presence of secreted mIL-12 from the cells, a mIL-12 p70 ReadySET-Go! ELISA kit was used following the manufacturer’s directions (eBioscience, San
Diego, CA, USA). Plates were read with a Bio-Rad model 680 microplate reader
(Hercules, CA, USA). Clones were compared using a one-way ANOVA with Tukey’s
post-test.
Isolation of mouse NK cells
Spleens were collected from C57BL/6 mice. A single cell suspension was prepared
using mechanical disruption with a 70 µm filter and centrifugation. All other cells were
depleted by magnetic labeling using a MACS NK cell isolation kit (Miltenyl Biotec,
Auburn, CA, USA).
IFN-γ production and Cytotoxicity of NK cells
Different clones and isolated mNK cells were plated on a 96 well plate at a ratio
of 1:3 in 200 µl NK media and incubated for 48 hours. After the incubation, 50 µl of
media was removed and analyzed for the presence of IFN-γ using BD OptiEIA mouse
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IFN-γ ELISA kit II (BD Pharmingen, San Jose, CA, USA) following the manufacturer’s
directions. The rest of the media was removed from the cells and 100 µl fresh NK media
was added. Cell proliferation was determined using Promega’s CellTiter 96 AQueous
nonRadioactive cell proliferation assay (Madison, WI, USA) following the
manufacturer’s instructions. Clones were compared using a one-way ANOVA with
Tukey’s post-test.
In vivo antitumor activity of MULT1E/mIL-12 fusion protein
C57BL/6 female mice were injected intravenously with 1-2x105 tumor cells in
0.5ml HBSS. Four weeks later, the mice were euthanized and the lungs were excised and
fixed with 4% paraformaldehyde. The tumor nodules on each lung were counted using a
dissecting microscope and the tumor weight was recorded. Clones were compared using
a one-way ANOVA with Tukey’s post-test.
Statistics
GraphPad software (Prism, San Diego, CA, USA) was used to plot graphs. Oneway or two-way analysis of variance (ANOVA) with Tukey’s post-tests or student t test
was used to perform the statistical analyses of the data. The significance was represented
as *p<0.05; **p<0.01 and ***p<0.001.
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CHAPTER FOUR

MICA/IL-12: A NOVEL BIFUNCTIONAL PROTEIN FOR KILLER CELL
ACTIVATION

Mrs. Ashlee Tietje and Dr. Yanzhang Wei
Department of Biological Sciences, Clemson University, Clemson, SC 29634

Abstract
Natural killer (NK) cells have the potential to be effective killers of tumor cells.
They are governed by inhibitory and activating receptors like NKG2D, whose ligands are
normally upregulated in cells that are stressed, like cancer cells. Advanced cancer cells,
however, have ways to reduce these ligands’ expression, leaving them less detectable by
NK cells. Along with these receptors, NK cells also require activating cytokines, like IL12. Previous work in our lab has shown that a fusion protein of the extracellular domain
of mouse UL-16 binding protein-like transcript 1 (MULT1E) and mouse Interleukin 12
(IL-12) can effectively activate mouse NK cells in in vitro assays and in in vivo animal
tumor models.100 The goal of this study is to expand the concept of developing a novel
bifunctional fusion protein for enhanced NK cell activation to human killer cells. The
proposed protein combines the extracellular domain of a human NKG2D ligand, MHC
class I polypeptide-related sequence A (MICA), and IL-12. It is hypothesized that when
expressed by tumor cells, the protein will activate human NK and other killer cells using
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the NKG2D receptor, and deliver IL-12 to the NK cells where it can interact with the IL12R and enhance cytotoxicity. The fusion protein, when expressed by engineered tumor
cells, indeed activated NK92 cells as measured by an increase in interferon-γ (IFN-γ)
production and an increase in cytotoxicity of tumor cells. The fusion protein was also
able to increase the proliferation of human peripheral blood mononuclear cells (PBMCs)
and augment their production of IFN-γ. This study along with the data from the previous
mouse studies suggests that the MICA/IL-12 bifunctional fusion protein represents an
effective activator of killer cells for cancer treatment.
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Introduction
Natural killer (NK) cells are part of the innate immune system and are one of the
primary cell types involved in anticancer immunosurveillance. At the onset of neoplastic
growth, tumor cells upregulate surface antigens, some of which are ligands for NK cell
activating receptors, including NKG2D. Once NK cells are activated, cytotoxic granules
are exocytosed into the extracellular space between the NK cell and the target cell and
apoptosis of target cells is induced.19 As the cancer progresses, however, advanced tumor
cells have found ways to downregulate surface NKG2D ligands. It has been shown that
the extracellular domains of MHC class-I related molecule A (MICA), a human NKG2D
ligand, can be shed by tumor cells by proteolytic cleavages, thus preventing activation of
cytotoxic immune cells.52 The immune system may also aid in selecting against tumor
cells that maintain NKG2D ligand expression.5 Due to these properties, MICA serves as
an excellent target for anti-cancer gene therapy.
Interleukin 12 (IL-12), also known as NK cell stimulatory factor 2, is an activator
and initiator of NK cell proliferation. IL-12’s activity is more efficient than either IL-2 or
the IFNs, requiring picomolar instead of nanomolar concentrations.65 In fact, NK cells
genetically engineered to express IL-12 in a membrane anchored form by mouse sonic
hedgehog C-terminal domain showed reduced (>10 fold) dependency on IL-2 and a
significantly prolonged survival time for tumor bearing mice receiving an intravenous
injection of these cells.95 IL-12 has been shown consistently to have potent anti-tumor
activity primarily through the activity of IFN-γ, the activation of CD8+ T cells, and the
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inhibition of angiogenesis.67,68
Previous work in our lab has shown that a bifunctional fusion protein containing
the mouse NKG2D ligand mouse UL-16 binding protein-like transcript 1 (MULT1) and
mouse IL-12 can effectively activate mouse NK cells both in vitro and in vivo leading to
a reduction in tumor size. It is believed that the enhanced antitumor effect is due to the
simultaneous activation of NK cells and other NKG2D expressing killer cells through the
MULT1/NKG2D pathway and the IL-12/IL-12R pathway. In addition, MULT1 may also
function as a carrier to deliver IL-12 directly to the killer cells. When the MULT1
domain binds to an NKG2D receptor on the surface of an NK cell, the IL-12 may also be
held in close proximity to IL-12 receptors on the same cell, which will maintain a high
level of IL-12 in the tumor microenvironment while providing low systemic IL-12 levels
and reduced toxicity.100
For this work to be translated for clinical use, the protein needs to be adapted for
use in humans. The purpose of this study is to develop a bifunctional fusion protein
containing a human NKG2D ligand, MICA, and IL-12. Since mouse IL-12 is fully
effective in engaging the human IL-12 receptor, a recombinant mouse IL-12 gene is used
in this model study. 101 This human version of the fusion protein was first examined by
transfecting the fusion gene into the human lung carcinoma cell line A549. Stable clones
of tumor cells expressing the fusion protein and control IL-12 or MICA proteins were
evaluated in a series of in vitro assays to determine their ability to activate the human
natural killer cell line NK92 and isolated PBMCs.
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Results
Construction of expression vectors
To construct the plasmid containing the MICA/IL-12 fusion gene, the MICA
extracellular domain cDNA sequence was amplified from pCMV-SPORT6-MICA and
used to replace MULT1E in the plasmid pcDNA3.1(+)MULT1E/mIL-12 that had been
constructed earlier in our lab.100 MICA was inserted directly upstream of a (GGGS)3
linker, allowing flexibility, and IL-12 in frame creating the new plasmid
pcDNA3.1(+)MICA/IL-12 (Figure 4.1). The IL-12 control plasmid, pcDNA3.1(+)IL-12,
was constructed by amplifying the IL-12 sequence from pORF-mIL-12 and ligating it
into the pcDNA3.1(+) vector. Since the fusion protein is secretable and only contains the
extracellular domain of MICA, PCR was used to amplify MICA from
pcDNA3.1(+)MICA/IL-12 and add a stop codon at the end of the extracellular domain.
Because MICA is a type I transmembrane protein and the signal sequence is conserved,
the resulting protein should be transported outside of the cell.102
Transfection and stable clone selection
A549 cells were transfected with plasmids pcDNA3.1(+)MICA/IL-12 (Figure
4.1), pcDNA3.1(+)MICA, or pcDNA(+)IL-12, respectively, using Lipofectamine.
Multiple clones from each transfection that were geneticin resistant were selected. RTPCR and ELISA analysis (see below) were used to screen these clones and clones M-IL/4
and M-IL/19 were selected for fusion protein MICA/IL-12, clone IL/14 for IL-12, and
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Figure 4.1. Plasmid pcDNA3.1(+)MICA/IL-12. The MICA extracellular domain sequence was amplified
from pCMV-SPORT6-MICA and used to replace MULT1E in the plasmid pcDNA3.1(+)MULT1E/mIL-12
that had been created earlier in our lab.100 MICA was inserted directly upstream of a (GGGS)3 linker
and IL-12 in frame creating the new plasmid pcDNA3.1(+)MICA/IL-12.

	
  

67	
  

clone M/19 for MICA. An in vitro cell proliferation assay shows that all clones grow at a
similar rate (data not shown).
Stable Clones Express the Fusion Protein
The fusion protein expression was first examined by reverse transcription-PCR
(RT-PCR) on total RNA samples collected from the clones using three pairs of primers.
The first pair was specific to a 177 bp portion of the extracellular domain of MICA. The
second pair amplified an 805 bp sequence of IL-12. The final primer pair amplified a 1.2
kb portion of the MICA/IL-12 fusion gene containing 446 bp of MICA, the (GGGS)3
linker, and 708 bp of IL-12. All cells, including the A549 control cells and IL/14, contain
mRNA transcripts for MICA (Figure 4.2A). The fusion gene clones, along with the
IL/14 clone contain mRNA transcripts for IL-12 (Figure 4.2B). Only clones M-IL/4 and
M-IL/19 contain mRNA transcripts for the MICA/IL-12 fusion gene (Figure 4.2C).
A sandwich ELISA detected the secretion of the transgene products. The
rhNKG2D/Fc chimera was used to coat the plate and anti-mouse IL-12 conjugated with
PE was used as the detecting antibody. Clone M-IL/4 produced significant levels of the
MICA/IL-12 fusion protein and successfully released it into the supernatant. Clone MIL/19 did not produce detectable amounts of the fusion protein (Figure 4.3A). ELISA
was also performed to detect IL-12 or MICA separately. Clones M-IL/4 and IL/14 both
produced similar amounts of IL-12 (Figure 4.3B). M-IL/19 produced no detectable levels
of IL-12. The secreted form of MICA was detected at significant levels in clones M-IL/4
and M/19 (Figure 4.3C).
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Figure 4.2 RT-PCR analysis of A549 clones with transgenes. Total RNAs were isolated from each clone and
reverse transcription was used to create cDNA. Primers were used to amplify a 177 bp portion of the
extracellular domain of MICA (A), a 805 bp portion of IL-12 (B), and a 1.2 kb portion of the MICA/IL-12
fusion gene containing 446 bp of MICA, the (GGGS)3 linker, and 708 bp of IL-12 (D) using PCR.	
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Figure 4.3. Detection of secreted transgene products from A549 clones. Supernatant from each clone was
collected for ELISA analysis. The fusion gene was detected by coating the plate with rhNKG2D/Fc
chimera, adding the supernatant, and using anti-mIL-12 antibody conjugated with PE as the detecting
antibody (A). IL-12 was detected using an mIL-12 ELISA kit (B). MICA was detected by coating the
plate with rhNKG2D/Fc chimera, adding the supernatant, and using anti-hMICA phycoerythrin
conjugated as the detecting antibody (C). Corrected RFU is calculated by subtracting background RFU
from each value. Clones were compared using a one-way ANOVA with Tukey’s post-test. *p<0.05 and
**p<0.01.
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MICA/IL-12 activates NK92 cells
Human NK92 cells were co-cultured with the A549 cells and clones M-IL/4, MIL/19, I/14, or M/19 for 48 hours. To determine if the proteins produced by these clones
could activate the NK92 cells, two assays were performed. First, 100 µl of the media was
removed and screened using an IFN-γ ELISA.	
  	
  The NK92 cells co-cultured with clones
M-IL/4, IL/14, and M/19 showed significantly higher IFN-γ production than NK92 cells
co-cultured with A549 parental cells. M-IL/19 was not able to significantly increase
IFN-γ production (Figure 4.4A).
The second assay measured primed NK92 cells’ cytotoxicity towards the tumor cell
clones. After removing the supernatants from the co-cultures, the wells were gently
rinsed five times with PBS to remove the remaining suspension NK92 cells and leave
behind the adherent tumor cells. The remaining cells were then measured using an MTS
cell proliferation assay. There were significantly fewer M-IL/4, M-IL/19, and IL/14 cells
when compared to the A549 parental cells. There was no significant difference in the
number of M/19 cells compared to the A549 parental cells (Figure 4.4B).
It is interesting to know if pre-activation or priming of NK92 cells with
supernatant collected from the clones expressing the fusion protein, IL-12, or MICA can
enhance the killing of parental A549 cells. A549 parental cells and the clones M-IL/4,
M-IL/19, IL/14, or M/19 were cultured in NK media for 48 hours before collecting the
supernatant. NK92 cells were then plated in the collected supernatants and allowed to
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Figure 4.4. NK92 cell activation. NK92 cells were co-cultured with different clones in a 96 well plate at a
ratio of 10:1 and incubated for 48 hours. After the incubation, media was removed and analyzed for the
presence of IFN-γ using ELISA (A). The NK92 cells’ cytotoxicity was determined by measuring the
proliferation of the tumor cells using Promega’s CellTiter 96 AQueous nonRadioactive cell proliferation assay
following the manufacturer’s instructions (B). NK92 cells primed with media collected from A549 clones
were co-cultured with parental A549 cells at a ratio of 10:1 for 24 hours. The amount of A549 cells
remaining after the incubation time was again measured using Promega’s CellTiter 96 AQueous
nonRadioactive cell proliferation assay following the manufacturer’s instructions. Corrected OD is
calculated by subtracting background OD from each value (C). Clones were compared using a one-way
ANOVA with Tukey’s post-test. *p<0.05, **p<0.01, and ***p<0.001.
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incubate for 48 hours. These primed NK92 cells were then plated with parental A549
cells at a ratio of 10:1 and incubated for 24 hours. At the end of the incubation, the
culture media was removed and the wells were gently rinsed five times to remove the
suspension NK92 cells and leave behind the adherent A549 cells. The remaining cells
were measured using an MTS cell proliferation assay. Although all NK92 cells, whether
primed or not, were able to significantly reduce the tumor cell number compared to the
control, M-IL/4 and M-IL/19 primed NK92 cells were able to kill significantly more
tumor cells than either A549, IL-4, or M/19 primed NK92 cells. Interestingly, unprimed
NK92 cells were the most effective killers of A549 cells (Figure 4.4C).
MICA/IL-12 activates human PBMCs
Human peripheral blood mononuclear cells (PBMCs) were isolated from
leukapheresis product using the Ficoll-Paque method. These cells were then cultured
with supernatants collected from A549 cells or clones M-IL/4, M-IL/19, M/19, or IL/14
for 10 days. To determine if the supernatants could promote PBMC proliferation, an
MTS cell proliferation assay was performed. Only supernatant collected from clone MIL/4 that expresses the fusion protein at a relatively high level was able to significantly
increase PBMC cell number (Figure 4.5A). An IFN-γ ELISA was also used to detect
killer cell activation. Clone M-IL/4 was also able to induce a significantly higher
production of IFN-γ when compared to clones M-IL/19 and IL/14. Clone M/19 also
induced production of a large amount of IFN-γ (Figure 4.5B). More interestingly,
PBMCs without co-culture expressed the highest level of IFN-γ.
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Figure 4.5. PBMC activation. Supernatant collected from A549 cells expressing the fusion protein, IL12, or MICA was used to activate isolated human PBMCs. After the incubation the relative cell
proliferation was determined using Promega’s CellTiter 96 AQueous nonRadioactive cell proliferation
assay (A) and the media was removed and analyzed for the presence of IFN-γ (B). Clones were
compared using a one-way ANOVA with Tukey’s post-test. *p<0.05, **p<0.01, and ***p<0.001.
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Discussion
Because NK cells play an important role in tumor immunosurveilance, many
strategies have been employed to harness their ability to prevent neoplastic growth. In
this study we developed a bifunctional fusion gene encoding MICA/IL-12, and
hypothesized that the bifunctional protein, when expressed by tumor cells, would
effectively activate NK cells and other NKG2D expressing killer cells in the tumor
environment and increase cytotoxicity.
RT-PCR indicates that all clones contained mRNA for MICA (Figure 4.2A). This
is not surprising since MICA is commonly expressed in lung carcinomas.103 IL-12
mRNA is detected in the two fusion gene clones (M-IL/4 and M-IL/19) and the IL-12
clone (IL/14) (Figure 4.2B). Finally, a portion of the MICA/IL-12 fusion protein
including the linker segment was detected only in the fusion gene clones M-IL/4 and MIL/19. This data indicates that the clones have in fact taken up the exogenous DNA and
transcription of the genes of interest can be detected.
It is important to demonstrate that the fusion protein is produced and being
released from the cell into the tumor microenvironment where it can interact with killer
cells. To test this, supernatants were collected from all the clones together with A549
cells and screened using ELISA. As Figure 4.3 shows, the engineered proteins are
produced by the respective clones and released from the cells into the supernatants.
Clone M-IL/4 produces a relatively high level of fusion protein MICA/IL-12, but it is not
detectable in the supernatant collected from M-IL/19 (Figure 4.3A). Because there was a
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clear band detected after RT-PCR indicating that M-IL/19 does contain the fusion gene, it
is possible that the protein amount produced by this clone is beneath the detection
threshold of the methods used. Both clones M-IL/4 and IL/14 produce significant levels
of IL-12. It should also be noted that the amount of IL-12 detected in the clone M-IL/4
supernatant is similar to the amount of IL-12 detected in the clone IL/14 supernatant.
This indicates that clone IL/14 is a good control for this experiment (Figure 4.3B). As
expected, significant levels of MICA were detected in the supernatants from clones MIL/4 and M/19. Since there is not a significant difference between the MICA levels of
clone M-IL/4 and M/19, clone M/19 is a good control for this experiment (Figure 4.3C).
To determine if fusion protein MICA/IL-12 is functional and has enhanced ability
to activate killer cells, a human natural killer cell line, NK92, was co-cultured with A549
cells and clones M-IL/4, M-IL/19, IL/14, and M/19 for 48 hours at a ratio of 10:1. The
amount of IFN-γ produced by the NK92 cells was evaluated with ELISA to determine the
level of NK cell activation. The NK92 cells co-cultured with clones M-IL/4, IL/14, and
M/19 showed significantly higher IFN-γ production than NK92 cells co-cultured with
A549 parental cells. Clone IL/14 was also able to increase IFN-γ production significantly
compared to NK92 cells that were not cultured with any A549 cells. 	
  M-IL/19 was not
able to significantly increase IFN-γ production compared to NK92 cells alone (Figure
4.4A). M-IL/4 stimulated production of similar levels of IFN-γ as clone IL/14, which is
expected because they both have similar IL-12 expression levels as shown in the IL-12
ELISA (Figure 4.3B). It is interesting that NK92 cells co-cultured with A549 parental
cells produced much less IFN-γ when compared with NK92 cells that were not co-
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cultured with any cells. This is possibly due to either the production of or the shedding of
inhibitory ligands from A549 tumor cells into the supernatant, a phenomenon commonly
seen in tumors, which can reduce the activation of the NK92 cells by engaging the
inhibitory receptors, such as NKG2A/B, KIR2DL4 and ILT-2.12,104–107 The results not
only confirm the notion that the activation of NK cells and other killer cells depends on
the balance of inhibitory receptors and activating receptors, but also demonstrate that the
fusion protein MICA/IL-12 can change the balance towards activation.
To determine if the fusion protein could enhance NK92 cytotoxicity toward the
tumor cells, the number of A549 cells remaining after the co-culture was measured.
There were significantly fewer cells of clones M-IL/4, M-IL/19, and IL/14 when
compared to the A549 parental cells or clone M/19 cells (Figure 4.4B). Although the
cytotoxicities among clones M-IL/4, M-IL/19, and IL/14 are not statistically different,
clone M-IL/4 shows a slightly higher activity. This indicates that clone M-IL/19 does
produce some MICA/IL-12 even though it was undetectable using ELISA (Figure 4.3C).
This suggests that when compared to a larger amount of IL-12, even a small amount of
the fusion protein can produce similar cytotoxic results. This is also interesting because
clone M-IL/19 was not able to increase IFN-γ production of the NK92 cells whereas MIL/4 and IL/14 were (Figure 4.4A). This suggests that the addition of the MICA portion
of the protein increases the cytotoxic activity of the NK92 cells.
One of the current hurdles for gene therapy is the low efficiency of gene
delivery.108 With this in mind, it is important to determine if MICA/IL-12 can also
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activate NK92 cells to kill A549 cells that do not express the protein. NK92 cells that
were primed for 48 hours with the supernatants from A549 cells and clones of M-IL/4,
M-IL/19, IL/14, and M/19 were co-cultured with parental A549 cells at a ratio of 10:1
and incubated 24 hours. After the removal of the suspension NK92 cells, the remaining
tumor cells were measured using an MTS cell proliferation assay. All NK92 cells,
whether primed or not, were able to significantly reduce the A549 cell number compared
to the control without NK92 cells. This is not a surprise as these cells are highly
cytolytic. Both clones M-IL/4 and M-IL/19 primed NK92 cells were able to kill
significantly more A549 cells than either A549, IL-4, or M/19 primed NK92 cells. This
suggests that priming with MICA/IL-12 is more effective than priming with either IL-12
or MICA alone, even when the amount of MICA/IL-12 is small as seen in clone M-IL/19.
Interestingly, the unprimed NK92 cells killed significantly more A549 cells than all other
NK92 cells except the NK92 cells primed with MICA/IL-12 (Figure 4.4C). This
suggests that MICA/IL-12 expression, even in small amounts, was able to overcome the
inhibitory signals from A549 cells during NK92 priming.
Although the NK92 cell line is a good model for human NK cells, it does not give a
complete picture of the in vivo effects of fusion protein MICA/IL-12. To better
understand how MICA/IL-12 will behave in a patient, further experiments were
conducted using human PBMCs isolated from leukapheresis products. Supernatants
collected from clones M-IL/4, M-IL/19, IL/14, or M/19 were used to treat PBMCs for 10
days and then a relative cell number was determined. Only supernatant from clone MIL/4, that expresses the highest level of the fusion protein, is able to significantly increase
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PBMC cell number (Figure 4.5A), indicating that MICA/IL-12 is able to either increase
proliferation and/or increase sustainability of these cells.
An IFN-γ ELISA was also used to detect NK and other killer cell activation in
PBMC culture. As Figure 4.5B shows, supernatant from clone M-IL/4 stimulates PBMCs
to produce the most IFN-γ, although supernatant from clone M/19 also stimulates
PBMCs to produce relatively high levels of IFN-γ. M-IL/4 induced a significantly higher
production of IFN-γ when compared to M-IL/19 and IL/14. (Figure 4.5C)
An interesting observation from this study is that the IFN-γ production by unprimed
PBMCs is significantly higher than those primed with any clones. This, again, is possibly
due to either the production of or the shedding of inhibitory ligands into the supernatant
by the tumor cells.12,104–106 This effect is more pronounced with the PBMCs compared to
NK92 cells (Figure 4.4A) as the IFN-γ production by unprimed PBMCs is higher than
that of PBMCs primed with supernatants from any of the tumor cell clones (Figure 4.5B),
while IFN-γ production by NK92 cells primed with clones M-IL/4, IL/14, or M/19 is
higher than that of the unprimed NK92 cells. This is probably due to the PBMCs’ larger
repertoire of inhibitory receptors. Although the fusion protein MICA/IL-12 did not
completely recover the inhibitory effects as it does in NK92 culture, it is much more
effective than IL-12 or MICA alone.
Another interesting observation seen when comparing the NK92 and the PBMC
results is the effectiveness of the IL/14 and M/19 clones. In the experiments conducted
using the NK92 cells, the clone that produced only IL-12 (IL/14) performed better than
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the clone that produced only MICA (M/19). The IL-12 was able to initiate production of
more IFN-γ by NK92 cells and resulted in more cell death during the co-culture
compared to M/19 (Figures 4.4A and 4.4B). However, in the PBMC experiments, clone
M/19 initiated the production of more IFN-γ by NK92 cells than was initiated by clone
IL/14 (Figure 4.5B). This suggests that the IL-12 may be a more effective activator of
NK cells, but the MICA can activate other killer cell types within the heterogeneous
PBMC population. The fusion protein, however, consistently outperforms both
individual components when tested separately.
In conclusion, a fusion protein containing the extracellular domain of the NKG2D
ligand MICA and IL-12 was successfully created and can be stably expressed by A549
tumor cells. The fusion protein can increase the production of IFN-γ by NK92 cells and
also increase the cytolytic activity of these cells toward A549 cells expressing MICA/IL12. The bystander effect was also demonstrated when MICA/IL-12 primed NK92 cells
were able to kill parental A549 cells significantly more than NK92 cells primed with
either IL-12 or MICA alone. This result was also an indication that the activation by
MICA/Il-12 was able to overcome inhibitory signals by the A549 cells. Preliminary
studies also indicate that MICA/IL-12 can increase proliferation and/or sustainability of
isolated human PBMCs. The data also suggests that MICA/IL-12 is effective at
augmenting the IFN-γ production of cells cultured with soluble inhibitory factors
produced by A549 cells. Although the study is preliminary, the data, along with the data
from the previous mouse studies suggest that the MICA/IL-12 bifunctional fusion protein
is an effective activator of killer cells for cancer treatment.
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Materials and Methods
Cells
The human lung carcinoma cell line A549 (ATCC no. CRM-CCL-185) was
cultured in F12K medium containing 10% fetal bovine serum (FBS) and 100 µg/ml
gentamicin at 37oC with 5% CO2. Human natural killer cell line (CRL-2407) NoGFPCD16.NK92 (PTA-6967) and the freshly isolated human PBMCs were cultured in αMEM with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 0.2 mM inositol, 0.1 mM β2mercaptoethanol, 0.02 mM folic acid, 200 U/ml recombinant IL-2, 12.5% horse serum,
12.5% FBS, and 100 µg/ml gentamicin at 37oC with 5% CO2. The blood samples were
procured following a GHS IRB approved protocol (CC/ORI 07-02) and the patients
consented that their blood materials would be used for research purposes.
Construction of fusion gene and control gene Vectors
pcDNA3.1(+)MICA/IL-12 The MICA extracellular domain sequence was amplified from
pCMV-SPORT6-MICA (Open Biosystems, Lafayette, CO, USA) using the 5’ primer
CCCAAGCTTGAGAGGGTGGCGACGTCGGGG, the 3’ primer CGGGATCCCTGCC
AATGACTCTGAAGCACC, and Phusion High-Fidelity DNA Polymerase. The 5’
primer contains a restriction cut site for HindIII and the 3’ primer contains the restriction
cut site for BamHI. The PCR fragment was excised and gel purified using a gel
purification kit. Double enzyme digestion using HindIII and BamHI was performed on
the purified fragment. The plasmid pcDNA3.1(+)MULT1E/mIL-12, created earlier in
our lab,100 was also digested with HindIII and BamHI to remove the MULT1E and

	
  

81	
  

allowing for the insertion of MICA directly upstream of a (GGGS)3 linker and IL-12 in
frame. The linearized plasmid was excised and gel purified using a gel purification kit.
The enzyme digested MICA PCR fragment was then ligated to the vector creating the
new plasmid pcDNA3.1(+)MICA/IL-12 (Figure 4.1). The sequence was confirmed using
DNA sequencing.
pcDNA3.1(+)IL-12 Vector To make a control IL-12 vector, the IL-12 sequence was
amplified from pORF-mIL-12 using the 5’ primer CCAAGCTTCCATGGGTCAATCAC
GCTACCTCC with a HindIII cut site and the 3’ primer CCTCGAGCTAGGATCGGAC
CCTGCAGGG with a XhoI restriction cut site using Phusion High-Fidelity DNA
Polymerase. The fragment was excised and gel purified using a gel purification kit.
Double enzyme digestion was performed on the purified fragment using HindIII and
XhoI. pcDNA3.1(+)Neo was digested with HindIII and XhoI allowing for the insertion
of IL-12. The fragment was excised and gel purified using a gel purification kit. The IL12 sequence was then ligated to pcDNA3.1(+)Neo creating the new plasmid
pcDNA3.1(+)IL-12. The sequence was confirmed using DNA sequencing.
pcDNA3.1(+) MICA Vector To make a control MICA vector encoding a secretable form
of the extracellular domain of MICA, the extracellular MICA sequence was amplified
from pcDNA3.1(+)MICA/IL-12. The 5’ primer was the same used for the construction
of pcDNA3.1(+)MICA/IL-12 and the 3’ primer (CCTCGAGCTACTGCCAATGACT
CT) included a stop codon and the restriction site for XhoI. PCR was performed to
amplify MICA using Phusion High-Fidelity DNA Polymerase. The fragment was
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excised and gel purified using a gel purification kit. Double enzyme digestion was
performed on the purified fragment using HindIII and XhoI. pcDNA3.1(+)Neo was
digested with HindIII and XhoI allowing for the insertion of MICA. The fragment was
excised and gel purified using a gel purification kit. The MICA sequence was then
ligated to the pcDNA3.1(+)Neo creating the new plasmid pcDNA3.1(+)MICA. The
sequence was confirmed using DNA sequencing.
Cell transfection
A549 cells were transfected with either pcDNA3.1(+)MICA/IL-12,
pcDNA3.1(+)IL-12, or pcDNA3.1(+)MICA using Lipofectamine as directed by the
manufacturer. To obtain stable clones, the transfected A549 cells were cultured in
medium containing 250 µg/ml G418. Drug-resistant clones were collected and
subcultured in the presence of the appropriate drug.
Proliferation Assay
To determine if the selected clones grow at the same rate as the untransfected
parental A549 cells, cells were counted every day for 5 days. On day one, 0.05x106 cells
per well were plated on 96 well plates in triplicates. At each time point, Promega’s
CellTiter 96 AQueous nonRadioactive cell proliferation assay was used following the
manufacturer’s instructions to determine the relative cell count. Clones were compared
using a two-way ANOVA with Tukey’s post-test.
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RT-PCR
Total RNA was extracted from each clone using an RNeasy Plus Mini Kit
following the manufacturer’s directions. RT-PCR was run using 1ug of the total RNA
using the Phusion RT-PCR kit following the manufacturer’s directions. To amplify a 177
bp segment from MICA the 5’ primer CCTTGGCCATGAACGTCAGG and the 3’
primer CCTCTGAGGCCTCGCTGCG were used. To amplify an 805 bp sequence of IL12 the 5’ primer GGGTGATGGGCTATCTGAGC and the 3’ primer AACTTGAGGGA
GAAGTAGGAATGG were used. To amplify a 1.2 kb portion of the MICA/IL-12 fusion
gene containing 446 bp of MICA, the (GGGS)3 linker, and 708 bp of IL-12 the 5’ primer
CCTTGGCCATGAACGTCAGG and the 3’ primer GGGAGTCCAGTCCAC CTCTA
were used. All reactions included the GAPDH housekeeping gene using the 5’ primer
ATGACATCAAGAAGGTGGTG and the 3’ primer CATACCAGGAAATGAGCTTG.
Detection of Secreted Protein
Cells of different clones were plated at 2x106 cells in 6 well plates with normal
growth media on day one. On day two, the media was removed, the cells were rinsed
with PBS, and serum free F12K was added. On day three, the serum free RPMI was
removed and centrifuged at 1000g for 15 min. The supernatant was then tested using an
appropriate immunofluorescence or ELISA protocol.
To detect the presence of MICA/IL-12, 96 well plates were coated with 2 µg/ml
rhNKG2D/Fc chimera in carbonate coating buffer and incubated overnight at 4oC. The
plates were rinsed with PBS and blocked with 10% FBS for 1.5 hours. After washing
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three times with PBS, 100µl of the cell supernatant was added to the plate in triplicates.
The samples were incubated at room temperature for 3 hours. After removing the
samples and washing the plates three times with PBS, 1 µg/ml PE rat anti-mouse IL-12
(p40/p70) in blocking solution was added to the plates. The plates were then incubated
for 1.5 hours at room temperature. After washing five times with PBS, the plates were
read with a BioTek Synergy H1 hybrid reader. Clones were compared using a one-way
ANOVA with Tukey’s post-test. Corrected RFU is calculated by subtracting background
RFU from each value.
To detect the presence of secreted IL-12 from the cells, a mIL-12 p70 ReadySET-Go! ELISA kit was used following the manufacturer’s directions. Plates were read
with a BioTek Eon microplate reader. Clones were compared using a one-way ANOVA
with Tukey’s post-test.
To detect the presence of MICA, 96 well plates were coated with 2 µg/ml
rhNKG2D/Fc chimera in carbonate coating buffer and incubated overnight at 4oC. The
plates were rinsed with PBS and blocked with 10% FBS for 1.5 hours. After washing
three times with PBS, 100µl of the cell supernatant was added to the plate in triplicates.
The samples were incubated at room temperature for 3 hours. After removing the
samples and washing the plates three times with PBS, 10 µl anti-hMICA phycoerythrin
conjugated in 90 µl blocking solution was added to the plates. The plates were then
incubated for 1.5 hours at room temperature. After washing five times with PBS, the
plates were read with a BioTek Synergy H1 hybrid reader. Clones were compared using
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a one-way ANOVA with Tukey’s post-test. Corrected RFU is calculated by subtracting
background RFU from each value.
NK92 and A549 Co-culture
NK92 cells were plated with A549 cells or clones expressing the fusion protein,
IL-12, or MICA on a 96 well plate at a ratio of 10:1 in 250 µl NK media and incubated
for 48 hours. After the incubation, 100 µl of media was removed and analyzed for the
presence of IFN-γ using Thermo’s human IFN-γ ELISA reagent kit following the
manufacturer’s directions. The rest of the media was removed from the cells, the NK
suspension cells were carefully rinsed off, and 100 µl fresh NK media was added. The
remaining tumor cell number was determined using Promega’s CellTiter 96 AQueous
nonRadioactive cell proliferation assay following the manufacturer’s instructions. Clones
were compared using a one-way ANOVA with Tukey’s post-test.
Primed NK92 Cytotoxicity
The A549 clones were plated on a 6 well plate in 5ml NK media at a density of
0.5 x 106 cells per well and incubated for 48 hrs. After the incubation, the supernatant
was collected from these cells and used to plate 4 x 105 NK92 cells on a 6 well plate.
After a 48 hr priming period, these NK92 cells were removed and plated on a 96 well
plate at a density of 5 x 104 cells per well with 0.5 x 104 parental A549 cells and
incubated for 24 hrs. After the incubation, the media was removed from the cells and the
wells were carefully washed four times to remove the non-adherant NK92 cells. 100 µl
fresh NK media was added. Cell proliferation was determined using Promega’s CellTiter
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96 AQueous nonRadioactive cell proliferation assay following the manufacturer’s
instructions. Clones were compared using a one-way ANOVA with Tukey’s post-test.
Corrected OD is calculated by subtracting background OD from each value
Preparation of human PBMCs
PBMCs were isolated from leukapheresis product using the Ficoll-Paque method.
Briefly, the blood product was mixed 1:4 with PBS and loaded on top of 30 ml
lymphocyte separation media and centrifuged for 15 min. The PBMC layer was then
removed and rinsed with PBS. ACK lysing buffer was then used to lyse any remaining
RBCs. After a final PBS rinse, cells were counted and used.
Supernatant Transfer to PBMC
The A549 clones were plated on a 6 well plate in 1.5ml PBMC media at a density
of 0.6 x 106 cells per well and incubated for 48 hrs. After the incubation, the supernatant
was collected from these cells and used to plate 2 x 105 freshly isolated PBMCs on a 96
well plate and the cells were incubated for 10 days. After the incubation, 100 µl of media
was removed and analyzed for the presence of IFN-γ using Thermo’s human IFN-γ
ELISA reagent kit following the manufacturer’s directions. The rest of the media was
removed from the cells and 100 µl fresh PBMC media was added. Cell proliferation was
determined using Promega’s CellTiter 96 AQueous nonRadioactive cell proliferation assay
following the manufacturer’s instructions. Clones were compared using a one-way
ANOVA with Tukey’s post-test.
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Statistics
GraphPad software was used to plot graphs and run statistics. The significance
was represented as *p<0.05; **p<0.01 and ***p<0.001.
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CHAPTER FIVE

CONCLUSIONS AND FUTURE DIRECTIONS

One of the characteristics of advanced tumors is the evasion of the immune
system. There are multiple methods that tumor cells employ to achieve this including
reducing the expression of activating ligands on the cell surface and a shift in the tumor
microenvironment toward pro-tumor cytokines. The purpose of this research is to
develop a novel bifunctional fusion protein that will target these two deficiencies in the
tumor microenvironment and activate killer cells that are already present.
The mouse form of a fusion gene encoding the extracellular domain of the
NKG2D ligand mouse UL-16-binding protein-like transcript 1 (MULT1E) and mouse IL12 (mIL-12) was created with modern DNA cloning technology:
pcDNA3.1(+)MULT1E/mIL-12. Mouse tumor cells were transfected with the fusion
gene construct. When expressed by the engineered tumor cells, the fusion protein
MULT1E/mIL-12 indeed activated NK cells in vitro as assayed by increased production
of IFN-γ and cytotoxicity. Tumor cells that produce the fusion protein were then
intravenously injected into female C57BL/6J mice to determine the anti-tumor activity in
vivo. MULT1E/mIL-12 significantly reduced the number of tumor nodules found on the
lungs after 4 weeks with the highest producing clone (M-IL/4) having no tumor nodules
at all. MULT1E/mIL-12 also performed better than both a clone that only produced the
MULT1E portion of the protein (MULT/6) and a clone that produced only the mIL-12
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portion of the protein (IL/3) in both in vitro and in vivo studies.
To expand the concept of developing a novel bifunctional fusion protein for
enhanced killer cell activation to human killer cells, the mouse NKG2D ligand MULT1
was replaced with the extracellular domain of a human NKG2D ligand MHC class I
polypeptide-related sequence A (MICA). The fusion protein, when expressed by
engineered tumor cells, indeed activated a human NK cell line, NK92, as measured by an
increase in IFN-γ production and an increase in cytotoxicity of tumor cells. In addition,
MICA/IL-12 was able to prime the NK92 cells and increase their cytotoxicity toward
tumor cells that did not produce the protein. This is important because it demonstrates
that even if gene delivery is not highly efficient, MICA/IL-12 can increase killing of nontransformed cells. This experiment also showed that the fusion protein was able to
counteract the inhibitory factors found in the tumor cell media and returns the killing
ability to uninhibited levels.
Although the NK92 cell line is a good model for human NK cells, it does not give
a complete picture of the in vivo effects of the fusion protein MICA/IL-12. To test this,
human peripheral blood mononuclear cells (PBMCs) collected from leukapheresis
products was tested. Only media containing the fusion protein was able to increase the
proliferation of human PBMCs while media containing just IL-12 or just MICA could
not. MICA/IL-12 was also able to augment PBMC production of IFN-γ.
This study suggests that a bifunctional fusion protein containing an NKG2D
ligand and IL-12 represents an effective activator of killer cells for cancer treatment,
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however there are still questions that need to be answered. First, what is the primary
mechanism of action in vivo? This question can be addressed by determining if NK cells
are in fact activated in vivo. To determine this, cells from different clones can be
inoculated in to NK cell-deficient beige KO mice (C57BL/6J-Lystobg-J/J)97 and tumor
development can be monitored. We speculate that the tumors will grow faster in beige
mice when compared with regular C57 BL/6J mice.
Also, in both the mouse and human studies, the NK cells performed differently
than the heterogeneous cell populations that contained other killer cells (the in vivo
mouse model and the PBMCs). This indicates that NK cells are not the only killer cell
population that is activated by the fusion protein. This is not surprising because other cell
types contain the NKG2D receptor and/or the IL-12 receptor including CD8+ T cells,
NKT cells, and CD4+ T cells.39,62,63 Once activated by IL-12, many of these cell types
produce IFN-γ which has many important biological functions including the activation of
type I macrophages.77 Several approaches could be used to identify the effector cell
types involved in the anti-tumor response seen in these experiments. The use of KO mice
has already been mentioned and may also prove beneficial in elucidating this question.
Additionally, lungs could be collected from mice that received the intravenous injection
of engineered tumor cells producing the fusion protein and stained to identify the specific
cell populations. This could be done either by immunohistochemistry or a more
quantitative number could be achieved after tissue disruption and FACS. A similar cell
staining and count method could be carried out on the PBMC culture after priming with
the fusion protein to determine which cell types are increased after activation.
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Furthermore, the activity may be a result of the production of IFN-γ that has been
shown to be one of the primary mediators of IL-12 activated anti-tumor activity.67 To
determine if the effects seen were modulated primarily by the fusion protein directly
activating killer cells or by the production of IFN-γ, a neutralizing antibody to IFN-γ
could be added.
Second, the pulmonary metastasis data cannot differentiate whether the fusion
protein prevents implantation of the tumor cells by causing killer cells to destroy them en
route or if killer cells destroy the tumor cells post-implantation. To answer this question,
a gene delivery vehicle can be used to deliver the fusion gene directly to already
established tumors. Adenoviral vectors have been used previously in our lab making
them a convenient choice.59 Adenoviral vectors can be produced that are cancer-specific
by including cancer-specific promoters, like the human telomerase (hTERT) promoter
that is active in 85-90% of tumor tissues but is inactive in most normal host tissues.109
We will also investigate the possibility of using nanoparticles to deliver the fusion gene
specifically to tumors using tumor-specific surface markers.110 Either of these
mechanisms will achieve the ultimate goal of making this novel fusion protein an
effective cancer immuno/gene therapy.
Another concern is the side effects of using this bifunctional protein. We did not
observe any side effects in the preliminary in vivo mouse study. The ultimate goal is to
use this fusion protein as a novel immuno/gene therapy. Once the delivery vehicle is
determined, future studies can more broadly analyze the effectiveness and potential side
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effects of this treatment. One of the key concerns will be how to make sure the gene is
delivered into tumor cells specifically, but not into other healthy cells because if the gene
is expressed by healthy cells, the fusion protein may activate NK cells in healthy tissues
and cause off-target effects and toxicity. Several methods to prevent this were mentioned
previously.
In conclusion, the novel fusion protein consisting of the extracellular domain of an
NKG2D ligand and IL-12 is an effective activator of killer cells both in vitro and in vivo.
This was shown in both mouse and human models. Because this novel fusion protein
activates killer cells that are part of the innate immune system that does not require the
use of tumor specific antigens, this therapy should be easily translatable to many different
tumor types. Using gene therapy to deliver the fusion protein directly to the tumor cells
will maintain a high level of IL-12 in the tumor microenvironment while providing low
systemic IL-12 levels, reducing toxicity.
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